

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

**THIS PAGE BLANK (USTRD)**

PCT/EP 00/00120

4  
EPOO/120

PA 200029

REC'D 02 MAR 2000

WIPO PCT

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office **09/889455**

January 28, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 09/232,738

FILING DATE: January 15, 1999

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



*L. Edele*

L. EDELEN  
Certifying Officer

Please type a plus sign (+) inside this box →

Approved for use through 09/30/00. OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. Bayer 10,159 Total Pages 1

First Named Inventor or Application Identifier

SEE ATTACHED APPENDIX

Express Mail Label No. EL210554490US

6673138  
S/6232138  
D/6232138

### APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2.  Specification [Total Pages 103]
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 USC 113) [Total Sheets \_\_\_\_\_]
4. Oath or Declaration [Total Pages \_\_\_\_\_]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
(Note Box 5 below)
    - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior application.  
see 37 CFR 1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a  
copy of the oath or declaration is supplied under Box 4b,  
is considered as being part of the disclosure of the  
accompanying application and is hereby incorporated by  
reference therein.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6.  Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

### ACCOMPANYING APPLICATION PARTS

8.  Assignment Papers (cover sheet & document(s))
9.  37 CFR 3.73(b) Statement [when there is an assignee]  Power of Attorney
10.  English Translation Document (if applicable)
11.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14.  Small Entity Statement filed in prior application,  
Statement(s)  Status still proper and desired
15.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16.  Other: STATEMENT UNDER 37 CFR  
1.41(C) .....

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation  Divisional  Continuation-In-part (CIP)

of prior application No. \_\_\_\_\_

### 18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

or  Correspondence address below

Print Customer No. or Attach bar code label here

NAME	Kurt G. Briscoe, Reg. No. 33,141				
	SPRUNG KRAMER SCHAEFER & BRISCOE				
ADDRESS	660 White Plains Road				
CITY	Tarrytown	STATE	NY	ZIP CODE	10591
COUNTRY	USA	TELEPHONE	(914) 332-1700	FAX	(914) 332-1844

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

M 17-02-00

Bayer 10,159-KGB:lad  
Le A 33 364-WI/Hen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Andreas SCHOOP, et al.  
Serial No. : TBA  
Filed : Herewith  
For :  $\beta$ -PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS  
Group Art Unit : TBA  
Examiner : TBA

---

January 15, 1999

Hon. Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, kindly amend the above-identified application as follows:

IN THE CLAIMS

Claim 12, line 2, cancel "Claims 1 to 10" and substitute --Claim 1--.

Claim 13, line 1, cancel "Claims 1 to 10" and substitute --Claim 1--.

Claim 14, line 1, cancel "Claims 1 to 10" and substitute --Claim 1--.

M 17-02-00

REMARKS


The foregoing amendment serves to eliminate multiple dependencies and place the claims in better form for U.S. examination.

Early and favorable action is earnestly solicited.

Respectfully submitted,

SPRUNG KRAMER SCHAEFER & BRISCOE

By:

  
Kurt G. Briscoe  
Reg. No. 33141

660 White Plains Road  
Tarrytown, NY 10591-5144  
(914) 332-1700

17-02-00

**β-Phenylalanine derivatives as integrin antagonists**

**Field of the invention**

5 The present invention relates to β-phenylalanine derivatives, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.

10

**Background of the invention**

Integrins are heterodimeric transmembrane proteins located on the surface of cells, which play an important part in the adhesion of cells to an extracellular matrix. They recognize extracellular glycoproteins such as fibronectin or vitronectin on the extracellular matrix by means of the RGD sequence occurring in these proteins (RGD is the single-letter code for the amino acid sequence arginine-glycine-aspartate).

20 In general, integrins such as, for example, the vitronectin receptor, which is also referred to as the  $\alpha_v\beta_3$  receptor, or alternatively the  $\alpha_v\beta_5$  receptor or the GpIIb/IIIa receptor, play an important part in biological processes such as cell migration and cell-matrix adhesion and thus in diseases in which these processes are crucial steps. Examples which may be mentioned are cancer, osteoporosis, arteriosclerosis, 25 restenosis (fresh occurrence of a stenosis after a surgical intervention as a result of damage to the vascular wall) and ophthalmia (a certain type of inflammation of the eye).

30 The  $\alpha_v\beta_3$  receptor occurs, for example, in large amounts on growing endothelial cells and makes possible their adhesion to an extracellular matrix. Thus the  $\alpha_v\beta_3$  receptor

M 17.02.00

plays an important part in angiogenesis, i.e. the formation of new blood vessels, which is a crucial requirement for tumor growth and metastasis formation in carcinomatous disorders. Furthermore, it is also responsible for the interaction between osteoclasts, i.e. cells resorbing mineralized tissue, and the bone structure.

5       The first step in the degradation of bone tissue consists in adhesion of osteoclasts to the bone. This cell-matrix interaction takes place via the  $\alpha_5\beta_3$  receptor, which is why the corresponding integrin plays an important part in this process. Osteolytic diseases such as osteoporosis are caused by an inequilibrium between bone formation and bone degradation, i.e. the resorption of bone material caused by addition of  
10      osteoclasts predominates.

15      It was possible to show that the blocking of the abovementioned receptors is an important starting point for the treatment of disorders of this type. If the adhesion of growing endothelial cells to an extracellular matrix is suppressed by blocking their corresponding integrin receptors, for example by a cyclic peptide or a monoclonal antibody, the endothelial cells die. Angiogenesis therefore does not occur, which leads to a stoppage or regression of tumour growth (cf., for example, Brooks et al., Cell, Volume 79, 1157-1164, 1994).


20      Moreover, the invasive properties of tumour cells and thus their ability for metastasis formation are markedly decreased if their  $\alpha_5\beta_3$  receptor is blocked by an antibody (Brooks et al., J. Clin. Invest., Volume 96, 1815, 1995).

25      The degradation of bone tissue can obviously be suppressed by blockage of the  $\alpha_5\beta_3$  receptors of the osteoclasts, since these are then unable to accumulate on the bone in order to resorb its substance (WO 98/18461, p.1, l. 24 to p.2, l. 13).

30      As a result of the blockage of the  $\alpha_5\beta_3$  receptor on cells of the aorta smooth vascular musculature with the aid of integrin receptor antagonists, it is possible to suppress the migration of these cells into the neointima and thus angioplasty leading to arteriosclerosis and restenosis (Brown et al., Cardiovascular Res., Volume 28, 1815,

1994).



In recent years, compounds have therefore been sought which act as antagonists of integrin receptors. For example, WO98/00395 discloses the para-substituted phenylalanine derivative (I), which exhibits an IC<sub>50</sub> value of 0.13 nM in an α,β<sub>3</sub> receptor assay and an IC<sub>50</sub> value of 0.16 nM in an α,β<sub>5</sub> receptor assay:



10       ω-Phenylcarboxylic acids having a phenyl residue which is linked to the phenyl group via a linker group and having a guanidine unit or a guanidine mimic are disclosed, for example in WO 97/36858, WO 97/36859, WO 97/36860 and WO 97/36862. According to these laid-open patent applications, the linker group can be an amide, sulphonamide, ester, urea, ether, thioether, sulphoxide, sulphone or ketone unit which may be extended by an additional methylene group, or can be a saturated or unsaturated alkylene bridge.

15       In particular, WO 97/36859, in addition to numerous substances comprised by a general formula, actually discloses 3-phenylpropionic acid derivatives such as (II) or (III). While the α-phenylalanine derivative (II) exhibits an IC<sub>50</sub> value of 0.18 nM with respect to its activity as an α,β<sub>3</sub> antagonist in in-vitro investigations, the succinic acid derivatives (III) have IC<sub>50</sub> values in the range from 38.7 to 141 nM in the same investigations:


M 17.02.00




R = OH, OEt, NHCH<sub>2</sub>COOH

WO 97/36862, in addition to numerous substances comprised by a general formula,  
 5 actually describes  $\beta$ -substituted propionic acid derivatives such as (IV) or (V). The sulphonamide-bridged derivative (IV) exhibits an IC<sub>50</sub> value of 16.7 nM with respect to its activity as an  $\alpha_1\beta_3$  antagonist in in-vitro investigations, while the amide-bridged derivatives (V) have IC<sub>50</sub> values in the range from 0.87 to 11.6 nM in the same investigations:

M 17-02-00




(IV)



(V)

R = methyl, isopropyl, phenyl, 3,5-difluorophenyl




None of the abovementioned laid-open patent applications, however, discloses  $\beta$ -phenylalanine derivatives or their activity as  $\alpha,\beta_3$  antagonists.

5

$\beta$ -Phenylalanine derivatives as  $\alpha,\beta_3$  antagonists are disclosed, for example, in US-5639765, WO 97/08145 and WO 97/36861, the linkage of the carboxyl residue to the central group consisting of two phenyl units bonded to one another via a linker group being carried out in these compounds, if a central group of this type is present at all, via the amino group. For example, the compound (VI) disclosed in WO 97/36861 exhibits an IC<sub>50</sub> value of 1.66 nM with respect to its activity as an  $\alpha,\beta_3$  antagonist in in-vitro investigations.

10

M 17-02-00




It was the object of the present invention to develop compounds which exhibit a high activity as integrin antagonists and in particular against the  $\alpha_v\beta_3$  and/or the  $\alpha_v\beta_5$  receptor.

#### Summary of the invention

The present object is achieved according to the invention by the  $\beta$ -phenylalanine derivatives defined below. In particular, it has emerged that the  $\beta$ -phenylalanine derivatives according to the invention have a very high activity as integrin antagonists, especially against the  $\alpha_v\beta_3$  and/or the  $\alpha_v\beta_5$  receptor.

The present invention relates to compounds of the general formula (1)



wherein

$R^1$  is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;

M 17-02-00

R<sup>2</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an optionally substituted alkenyl residue, an optionally substituted alkinyl residue, a hydroxyl residue or an alkoxy residue or is bonded to R<sup>3</sup> with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>2</sup> is bonded and can optionally contain heteroatoms;

5 R<sup>3</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an optionally substituted alkenyl residue, an optionally substituted alkinyl residue, a hydroxyl residue or an alkoxy residue or is bonded to R<sup>2</sup> with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>3</sup> is bonded and can optionally contain heteroatoms;

10 R<sup>4</sup> is -SO<sub>2</sub>R<sup>4'</sup>, -COOR<sup>4''</sup>, -COR<sup>4''</sup>, -CONR<sup>4''</sup><sub>2</sub> or -CSNR<sup>4''</sup><sub>2</sub>;

15 R<sup>4'</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;

20 R<sup>4''</sup> is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;

25 R<sup>5</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue or a substituted or unsubstituted aryl residue;

30 R<sup>10</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom;

R<sup>11</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom;

30 L is -(CH<sub>2</sub>)<sub>m</sub>NHSO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NH(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>NHCO(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>CONH(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>OCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-,

M 17.02.00

- 5            -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>n</sub>-,    -(CH<sub>2</sub>)<sub>m</sub>COO(CH<sub>2</sub>)<sub>n</sub>-,    -(CH<sub>2</sub>)<sub>m</sub>OOC(CH<sub>2</sub>)<sub>n</sub>-,  
           -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>CO(CH<sub>2</sub>)<sub>n</sub>-,    -(CH<sub>2</sub>)<sub>m</sub>COCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-,    -NHCONH-,  
           -(CH<sub>2</sub>)<sub>m</sub>SCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-,    -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>S(CH<sub>2</sub>)<sub>n</sub>-,    -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO(CH<sub>2</sub>)<sub>n</sub>-,  
           -(CH<sub>2</sub>)<sub>m</sub>SOCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-,                  -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-                  or  
           -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, wherein m and n are each an integer of 0 or 1  
           and m + n ≤ 1;
- 10           R<sup>6</sup>        is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue,  
                   a substituted or unsubstituted aryl residue, a saturated or unsaturated,  
                   optionally substituted heterocyclic residue or is bonded to one of R<sup>7</sup>,  
                   R<sup>8</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted  
                   heterocyclic ring system which includes the nitrogen atom to which R<sup>6</sup>  
                   is bonded and can be saturated or unsaturated and/or can contain  
                   further heteroatoms;
- 15           X        is N, O or S;
- 15           R<sup>7</sup>        is absent, is -H, a substituted or unsubstituted alkyl or cycloalkyl  
                   residue, -NO<sub>2</sub>, -CN, -COR<sup>7</sup>, -COOR<sup>7</sup>, or is bonded to one of R<sup>6</sup>, R<sup>8</sup> or  
                   R<sup>9</sup> with formation of an optionally substituted heterocyclic ring  
                   system which includes X and can be saturated or unsaturated and/or  
                   can contain further heteroatoms;
- 20           R<sup>7</sup>        is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue,  
                   a substituted or unsubstituted aryl residue or a saturated or  
                   unsaturated, optionally substituted heterocyclic residue which can be  
                   saturated or unsaturated and/or can contain further heteroatoms;
- 25           R<sup>8</sup>        is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue,  
                   a substituted or unsubstituted aryl residue, a saturated or unsaturated,  
                   optionally substituted heterocyclic residue or is bonded to one of R<sup>6</sup>,  
                   R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted  
                   heterocyclic ring system which includes the nitrogen atom to which R<sup>8</sup>  
                   is bonded and can be saturated or unsaturated and/or can contain  
                   further heteroatoms;
- 30

M 17.00.00

R<sup>9</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;

and their physiologically acceptable salts and stereoisomers.

10 According to the invention, preferred compounds of the formula (1) are those in  
which

R<sup>1</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof;

15 R<sup>2</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue, an alkenyl residue, an alkinyl residue or a substituted derivative thereof; a hydroxyl residue or a C<sub>1-6</sub>-alkoxy residue or is bonded to R<sup>3</sup> with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>2</sup> is bonded and can optionally contain heteroatoms;

20 R<sup>3</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue, an alkenyl residue, an alkinyl residue or a substituted derivative thereof; a hydroxyl residue or a C<sub>1-6</sub>-alkoxy residue or is bonded to R<sup>2</sup> with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>3</sup> is bonded and can optionally contain heteroatoms;

25 R<sup>4</sup> is -SO<sub>2</sub>R<sup>4'</sup>, -COOR<sup>4''</sup>, -COR<sup>4'</sup>, -CONR<sup>4'2</sup> or -CSNR<sup>4'2</sup>;

R<sup>4'</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;

M 17:00:00

- 10 -

- R<sup>4</sup> is a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- 5 R<sup>5</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a C<sub>1-6</sub>-alkoxy residue or a substituted derivative thereof;
- R<sup>10</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a C<sub>1-6</sub>-alkoxy residue or a substituted derivative thereof or F, Cl, Br or I;
- R<sup>11</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or F, Cl, Br or I;
- 10 L is -NHSO<sub>2</sub>-, -CH<sub>2</sub>NHSO<sub>2</sub>-, -NHSO<sub>2</sub>CH<sub>2</sub>-, -SO<sub>2</sub>NH-, -CH<sub>2</sub>SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCH<sub>2</sub>-, -NHCO-, -CH<sub>2</sub>NHCO-, -NHCOCH<sub>2</sub>-, -CONH-, -CH<sub>2</sub>CONH-, -CONHCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-  
-CH<sub>2</sub>CH<sub>2</sub>O-, -COO-, -CH<sub>2</sub>COO-, -COOCH<sub>2</sub>-, -OOC-, -OOCCH<sub>2</sub>-, -CH<sub>2</sub>OOC-, -CH<sub>2</sub>CO-, -COCH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CO-, -COCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>COCH<sub>2</sub>-, -NHCONH-, -SCH<sub>2</sub>-, -CH<sub>2</sub>S-, -CH<sub>2</sub>SCH<sub>2</sub>, -SCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>S-, -SOCH<sub>2</sub>-, -CH<sub>2</sub>SO-, -CH<sub>2</sub>SOCH<sub>2</sub>-, -SOCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO-, -SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-,
- 15 R<sup>6</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>6</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;
- 20 X is O, N or S;
- R<sup>7</sup> is absent, is -H, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, -NO<sub>2</sub>, -CN, -COR<sup>7</sup>, -COOR<sup>7</sup>, or is bonded to one of R<sup>6</sup>, R<sup>8</sup> or R<sup>9</sup> with formation of an optionally substituted heterocyclic ring system which includes X and can be saturated or unsaturated and/or can contain further heteroatoms;
- 25 30

1700000

- 11 -

- R<sup>7</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof;
- R<sup>8</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>8</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms; and
- R<sup>9</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms.
- Particularly preferred compounds of the formula (I) according to the present invention are those in which
- R<sup>1</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof;
- R<sup>2</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -OH, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, benzyloxy or is bonded to R<sup>3</sup> with formation of an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>2</sup> is bonded and can optionally contain heteroatoms;
- R<sup>3</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl,


M 17.02.00

- 5        cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -OH, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, or is bonded to R<sup>2</sup> with formation of an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>3</sup> is bonded and can optionally contain heteroatoms;
- 10      R<sup>4</sup>      is -SO<sub>2</sub>R<sup>4'</sup> or -COR<sup>4'</sup>;
- 15      R<sup>4'</sup>      is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonylpiperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-methyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimeth-


yl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl, 8-quinolinyl;

R<sup>5</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl or


D 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100




(a1)




(a2)




(a3)



(a4)




(a5)




(a6)




(a7)




(a8)



(a9)




(a10)




10


(a11)




(a12)



(a13)






(a14)



(a15)

M 17.02.00





(a16)

(a17)

(a18)

(a19)

(a20)




(a21)

(a22)


(a23)

(a24)



(a25)

(a26)



(a27)

(a28)

R<sup>10</sup>

is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, fluorine, chlorine, bromine or iodine;

5

R<sup>11</sup>

is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, fluorine, chlorine, bromine or iodine;

10

L

is -NHSO<sub>2</sub>- , -CH<sub>2</sub>NHSO<sub>2</sub>- , -NHSO<sub>2</sub>CH<sub>2</sub>- , -SO<sub>2</sub>NH- , -CH<sub>2</sub>SO<sub>2</sub>NH- , -SO<sub>2</sub>NHCH<sub>2</sub>- , -NHCO- , -CH<sub>2</sub>NHCO- , -NHCOCH<sub>2</sub>- , -CONH- , -CH<sub>2</sub>CONH- , -CONHCH<sub>2</sub>- , -OCH<sub>2</sub>- , -CH<sub>2</sub>OCH<sub>2</sub>- , -OCH<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>O- or -CH<sub>2</sub>CH<sub>2</sub>O- ;

M 17-02-00

- 15 -

- R<sup>6</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one of the residues (a1) to (a28) or is bonded to one of R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic 4- to 6-membered ring system which includes the nitrogen atom to which R<sup>6</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;
- X is N, O or S;
- R<sup>7</sup> is absent, is -H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, -NO<sub>2</sub>, -CN, -COR<sup>7</sup>, -COOR<sup>7</sup> or is bonded to one of R<sup>6</sup>, R<sup>8</sup> or R<sup>9</sup> with formation of an optionally substituted carbocyclic or heterocyclic 4- to 6-membered ring system which includes X and can be saturated or unsaturated and/or can contain further heteroatoms;
- R<sup>7</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof;
- R<sup>8</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one of the residues (a1) to (a28) or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic 4- to

M 17:02:00

6-membered ring system which includes the nitrogen atom to which R<sup>8</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms; and

R<sup>9</sup>

5

is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one of the residues (a1) to (a28) or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic 4- to 6-membered ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms.

10

00  
01  
02  
03  
04  
05  
06  
07  
08  
09  
10  
11  
12  
13  
14  
15

15

According to a preferred embodiment, the present invention relates to compounds of the formula (1) in which

R<sup>4</sup> is -SO<sub>2</sub>R'<sup>4</sup>;

20

R'<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxy-carbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethyl-phenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(−)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl,

30

M 17-02-00

- 17 -

3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl,  
2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethyl-  
phenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl,  
2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxy-  
phenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoro-  
methylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-  
acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-  
chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-  
yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl,  
benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-  
methyl, 2,2-dimethyllethenyl, 2-chloropyridine-5-methyl, 5,7-  
dimethyl-1,3,4-triazaindolizin-2-yl, (S)-camphan-1-yl, (R)-camphan-  
1-yl or 8-quinolinyl;

10

L is  $\text{-NHSO}_2-$ ,  $\text{-CH}_2\text{NHSO}_2-$ ,  $\text{-NHSO}_2\text{CH}_2-$ ;

15

X is N;

and the other residues are as defined above.

According to a further preferred embodiment, the present invention relates to compounds of the formula (1) in which

20

 $\text{R}^4$  is  $\text{-COR}'$ ; $\text{R}'$  is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof,  $\text{-C}_6\text{H}_2(\text{CH}_3)_3$ ,  $\text{-C}_6(\text{CH}_3)_5$ ,  $\text{-CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl,

25

3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenyl-

30

M 17.00 · 00

- 18 -

propyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)anilin, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methylbenzothiazol-2-yl, N-methoxycarbonylpiperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-methyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl;

L is  $\text{-NHSO}_2^-$ ,  $\text{-CH}_2\text{NHSO}_2^-$  or  $\text{-NHSO}_2\text{CH}_2^-$ ;  
X is N;

and the other residues are as defined above.

According to yet a further preferred embodiment, the present invention relates to compounds of the formula (1) in which

R<sup>4</sup> is  $\text{-SO}_2\text{R}^4$ ;

R<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof,  $-\text{C}_6\text{H}_2(\text{CH}_3)_3$ ,  $-\text{C}_6(\text{CH}_3)_5$ ,  $-\text{CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxy-carbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethyl-

M 17-02-00

phenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl,  
phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl,  
1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-  
phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl,  
5  
3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl,  
2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethyl-  
phenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl,  
2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxy-  
phenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoro-  
methylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-  
10  
acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-  
chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-  
yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl,  
benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-  
methyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-  
15  
dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-  
1-yl or 8-quinoliny;  
  
L is -NHCO-, -CH<sub>2</sub>NHCO- or -NHCOCH<sub>2</sub>-;  
X is N;  
20  
and the other residues are as defined above.

According to yet a further preferred embodiment, the present invention relates to compounds of the formula (1) in which

R<sup>4</sup> is -SO<sub>2</sub>R<sup>4</sup>;  
25 R<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl,  
isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,  
cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted  
derivative thereof, -C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chloro-  
phenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-  
30 dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-  
dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-

17.02.00

5

dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxy-carbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethyl-phenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethyl-phenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxy-phenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolizin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl;

10

15

20

L is  $-OCH_2-$ ,  $-CH_2O-$ ,  $-CH_2OCH_2-$ ,  $-CH_2CH_2O-$  or  $-OCH_2CH_2-$ ;

X is N;

and the other residues are as defined above.

25

According to yet a further preferred embodiment, the present invention relates to compounds of the formula (1) in which

R<sup>4</sup> is  $-SO_2R^4$ ;

R<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof,  $-C_6H_2(CH_3)_3$ ,  $-C_6(CH_3)_5$ ,  $-CH_2C_6H_2(CH_3)_3$ , 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-

30

M 17-02-00


- 21 -

- dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxy-carbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethyl-phenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethyl-phenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxy-phenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoro-methylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridine-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-methyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl;
- L is  $\text{-NHSO}_2^-$ ,  $\text{-CH}_2\text{NHSO}_2^-$  or  $\text{-NHSO}_2\text{CH}_2^-$ ;
- X is N;
- R<sup>7</sup> and R<sup>9</sup> together form an ethylene group which bonds the nitrogen atom to which R<sup>7</sup> is bonded to the nitrogen atom to which R<sup>9</sup> is bonded; and the other residues are as defined above.

The present invention furthermore relates to a process for the preparation of compounds of the formula (1)


M 17-02-00

- 22 -



comprising the steps

- a) reaction of a  $\beta$ -amino acid of the formula (2)




where

P is  $-(CH_2)_mNO_2$ ,  $-(CH_2)_mO-C_{1-6}$ -alkyl,  $-(CH_2)_mSO_2P'$ ,  $-(CH_2)_mCOP'$ ,  
 $-(CH_2)_mCH_2O-C_{1-6}$ -alkyl, where m in each case is an integer of 0 or 1;

10 P' is  $-OH$ ,  $-O-C_{1-6}$ -alkyl,

and the other residues are as defined above;

with a compound R4-A to give a compound of the formula (3),



15 where

R4 is  $-SO_2R^{4''}$ ,  $-COOR^{4''}$ , or  $-COR^{4''}$ ;

R4 and R4'' are as defined above;

A is  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O$ -triflyl,  $-O$ -tosyl,  $-O-C_{1-6}$ -alkyl,  $-O-CO-C_{1-6}$ -alkyl,  
 $-O-CO-O-C_{1-6}$ -alkyl,  $-OC(CH_3)=CH_2$ ;

M 17.02.00

and the other residues are as defined above;


- b) conversion of the residue P into the residue Q, where

5        Q      is     $-(CH_2)_m NH_2$ ,     $-(CH_2)_m OH$ ,     $-(CH_2)_m CH_2OH$ ,     $-(CH_2)_m SO_2A$ ,  
 $-(CH_2)_m COA$ ,

A      is as defined above;

m      is an integer of 0 or 1;

- 10        c) reaction of the compound obtained from step b) with a compound of the formula (4)




where

15        S      is  $ASO_2(CH_2)_n^-$ ,  $NH_2(CH_2)_n^-$ ,  $ACO(CH_2)_n^-$ ,  $HOCH_2(CH_2)_n^-$ ,  $M(CH_2)_n^-$ ,  
 $MCH_2(CH_2)_n^-$ ,  $HSCH_2(CH_2)_n^-$  or  $HS(CH_2)_n^-$ , where n is an integer of  
0 or 1;

M      is a residue including Mg, Li, Cd or Sn;

A      is as defined above; and

C      is  $-NO_2$  or




20        X, R^7, R^8, R^9 and R^11 are as defined above;

to give a compound of the formula (5)

M 17-02-00


-24-



where the residues are as defined above;

- 5      d) if appropriate, conversion of C, if C is a nitro group, into an optionally cyclic urea, thiourea or guanidine unit with obtainment of the compound (1); and
- 10     e) if appropriate, removal of protective groups and/or derivatization of nitrogen atoms, which are present at preferred times within the preparation process, and/or conversion of the compound obtained into the free acid and/or conversion of the compound obtained into one of its physiologically acceptable salts by reaction with an inorganic or organic base or acid.

15     Preferably, in the process according to the invention the  $\beta$ -amino acid of the formula (2) is obtained by reaction of malonic acid with a benzaldehyde derivative of the formula (2a)



20     where R<sup>10</sup> and P are as defined above, in the presence of ammonia, ammonium compounds or amines and, if appropriate, subsequent substitution in the  $\alpha$ -position to the terminal carboxyl group.

M 17.02.00

- 25 -

Furthermore, according to a preferred embodiment of the invention, the process comprises the conversion of the nitro group in step d) by reduction to the amino group, subsequent reaction with a carbonic acid ester derivative and, if appropriate, removal of protective groups present and/or reaction with a compound containing at 5 least one amino group.

The present invention furthermore relates to a pharmaceutical composition which contains at least one of the compounds according to the invention described above.

10 The present invention furthermore relates to the use of the compounds according to the invention described above for the production of a pharmaceutical composition having integrin-antagonistic action.

15 The present invention furthermore relates to the use of the compounds according to the invention described above for the production of a pharmaceutical composition for the therapy and prophylaxis of cancer, osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis and ophthalmic disorders.

**Detailed description of the preferred embodiments**

20 The invention is explained more exactly below with reference to preferred embodiments to which, however, it is not restricted in any way. In the description below, bivalent substituents are indicated in such a way that their respective left end is connected to the group indicated left of the corresponding substituent in formula 25 (1), and their respective right end is connected to the group indicated right of the corresponding substituent in formula (1). If, for example, the residue L is  $-(CH_2)_mNHSO_2(CH_2)_n-$  in formula (1), the nitrogen atom is connected to the phenylene group located left of the residue L in formula (1) by means of the group  $(CH_2)_m$ .

30

M 17.02.00

- The compounds according to the invention are characterized in that, as a main structural element, they have two phenyl units connected via a linker group L, one phenylene group of which has the residue derived from a  $\beta$ -amino acid, while the other phenylene group carries a urea group, thiourea group or guanidine group optionally incorporated into a cyclic ring system. The phenylene units bonded by a linker group L can moreover carry further substituents in addition to the abovementioned residues.
- The terminal carboxyl unit included in the residue derived from a  $\beta$ -amino acid can be present as a free carboxylic acid or as an ester. In the case in which the terminal carboxyl unit is esterified, basically all carboxylic acid esters obtainable according to conventional processes and which can be metabolized into the free carboxylic acid in the animal body, such as the corresponding alkyl esters, cycloalkyl esters, aryl esters and heterocyclic analogues thereof can be used according to the invention, where alkyl esters, cycloalkyl esters and aryl esters are preferred and the alcoholic residue can carry further substituents. C<sub>1-6</sub>-Alkyl esters such as the methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, isopentyl ester, neopentyl ester, hexyl ester, cyclopropyl ester, cyclopropylmethyl ester, cyclobutyl ester, cyclopentyl ester, cyclohexyl ester, or aryl esters such as the phenyl ester, benzyl ester or tolyl ester are particularly preferred.
- The abovementioned esters can be employed as prodrugs for the treatment of the diseases mentioned at the beginning, such as cancer, osteoporosis, arteriosclerosis, restenosis or ophthalmia, since they are easily converted in an animal and in man to the corresponding carboxylic acid. However, for the treatment of the abovementioned disorders the compounds of the general formula (1) according to the invention are preferably used in a form in which the terminal carboxyl unit is present as a free carboxylic acid.
- For medicinal use, the compounds of the general formula (1) according to the invention can also be employed in the form of their physiologically acceptable salts.

M 17.02.00

Physiologically acceptable salts are understood according to the invention as meaning non-toxic salts, which in general are accessible by reaction of the compounds of the general formula (1) according to the invention with an inorganic or organic base or acid conventionally used for this purpose. Examples of preferred salts  
5 of the compounds of the general formula (1) according to the invention are the corresponding alkali metal salt, e.g. the lithium, potassium or sodium salt, the corresponding alkaline earth metal salt such as the magnesium or calcium salt, a quaternary ammonium salt such as, for example, the triethylammonium salt, acetate, benzenesulphonate, benzoate, dicarbonate, disulphate, ditartrate, borate, bromide,  
10 carbonate, chloride, citrate, dihydrochloride, fumarate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulphate, nitrate, oleate, oxalate, palmitate, pantothenate, phosphate, diphosphate, polygalacturonate, salicylate, stearate, sulphate, succinate, tartrate, tosylate and valerate, and other salts used for medicinal purposes.  
15

The residue bonded to one of the two central phenylene units and derived from a  $\beta$ -amino acid can alternatively carry one or two additional substituents in the  $\alpha$ -position to the carboxyl group. These substituents can in each case be selected from the group which consists of hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an optionally substituted alkenyl residue, an optionally substituted alkinyl residue, a hydroxyl residue or an alkoxy residue. The alkyl residue can preferably be a C<sub>1-6</sub>-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl. The cycloalkyl residue can preferably be a C<sub>3-7</sub>-cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The aryl residue can preferably be phenyl, benzyl or tolyl. The heterocyclic residue can preferably be pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, thioxazole, benzofuran, quinoline, isoquinoline or pyrimidine.  
20  
25  
30 The alkenyl residue can be a terminal or internal E or Z alkene unit. The alkoxy

M 17.02.00

- 28 -

- residue can preferably be a C<sub>1-6</sub>-alkoxy residue such as, for example, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy or benzyloxy. The abovementioned residues can alternatively be substituted by one or more C<sub>1-6</sub>-alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl, C<sub>3-7</sub>-cycloalkyl residues such as cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or cyclohexyl, aryl residues such as phenyl, benzyl, tolyl, naphthyl, heterocyclic residues such as pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, oxazole, thiazole, thioxazole, benzofuran, benzoxazole, benzothiazole, quinoline, isoquinoline, or functional groups such as a double bond to a heteroatom such as oxygen, sulphur or nitrogen, an optionally substituted amino group, a nitro group, a halogen, a hydroxyl group, an ether group, a sulphide group, a mercaptan group, a cyano group, an isonitrile group, an alkenyl group, an alkinyl group, an aldehyde group, a keto group, a carboxyl group, an ester group, an amide group, a sulphoxide group or a sulphone group. One or more additionally saturated or unsaturated rings can furthermore be fused to the abovementioned cyclic residues with formation of, for example, a naphthyl, benzofuranyl, benzoxazolyl, benzothiazolyl, quinolinyl or isoquinolinyl unit or a partially or completely hydrogenated analogue thereof.
- The two substituents in the  $\alpha$ -position to the terminal carboxyl group, if present, can furthermore be bonded to one another and can thus together form a carbocyclic or heterocyclic ring system together with the  $\alpha$ -carbon atom of the residue derived from a  $\alpha$ -amino acid. This ring system can optionally carry further substituents and/or contain further heteroatoms. According to the invention, the above ring system, if present, is preferably a 3- to 6-membered carbocyclic or heterocyclic ring system such as, for example, a cyclopropane ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, dihydrofuran ring, tetrahydrofuran ring, dihydropyran ring, tetrahydropyran ring, dioxane ring, dihydrothiophene ring, tetrahydrothiophene ring or a substituted derivative thereof.

In the groups according to the invention, the amino group included in the residue derived from a  $\beta$ -amino acid is substituted by one of the residues  $-\text{SO}_2\text{R}^4$ ,  $-\text{COOR}^4$ ,  $-\text{COR}^4$ ,  $-\text{CONR}^4$ , or  $-\text{CSNR}^4$ , where  $\text{R}^4$  can be hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue and  $\text{R}^{4''}$  can be a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue. In this context, the alkyl residue is preferably a  $\text{C}_{1-6}$ -alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, the cycloalkyl residue is a  $\text{C}_{3-7}$ -cycloalkyl such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, the aryl residue is an aryl such as phenyl, benzyl, tolyl or a substituted derivative thereof such as  $-\text{C}_6\text{H}_2(\text{CH}_3)_3$ ,  $-\text{C}_6(\text{CH}_3)_5$ ,  $-\text{CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(−)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)-aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolizin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl.

M 17-02-00

According to the invention, the amino group included in the residue derived from a  $\beta$ -amino acid is particularly preferably substituted by  $-\text{SO}_2\text{R}^4$  or  $-\text{COR}^4$ , where  $\text{R}^4$  is as defined above. In this context, compounds are particularly preferred in which the residue derived from a  $\beta$ -amino acid has no substituent in the  $\alpha$ -position to the carboxyl unit and the amino group included in this residue is substituted by  $-\text{SO}_2\text{R}^4$  or  $-\text{COR}^4$ , where  $\text{R}^4$  is as defined above.

In addition to one of the abovementioned residues, the nitrogen atom of the amino group situated in the  $\beta$ -position can have a substituent which can be from the group consisting of hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue or can be bonded to one another and can thus form a heterocyclic ring system together with the nitrogen atom(s) to which they are bonded.


In this context, substituents are preferred which can be selected from the group consisting of hydrogen, a  $\text{C}_{1-6}$ -alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl, a  $\text{C}_{3-7}$ -cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, an aryl such as, for example, phenyl, benzyl or toyl, a heterocyclic residue such as, for example, pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazazole, benzofuran, benzoxazole, benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine and can alternatively be substituted by one or more  $\text{C}_{1-6}$ -alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl,  $\text{C}_{3-7}$ -cycloalkyl residues such as cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or cyclohexyl, aryl residues such as phenyl, benzyl, toyl, naphthyl, indolyl, heterocyclic residues such as pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazazole, benzofuran, benzoxazole,

M 17.02.00


benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine, or functional groups such as a double bond to a heteroatom such as oxygen, sulphur or nitrogen, an optionally substituted amino group, a nitro group, a halogen, a hydroxyl group, an ether group, a sulphide group, a mercaptan group, a cyano group, an isonitrile group, an alkenyl group, an alkinyl group, an aldehyde group, a keto group, a carboxyl group, an ester group, an amide group, a sulphoxide group or a sulphone group. One or more additionally saturated or unsaturated rings can furthermore be fused to the abovementioned cyclic residues with formation of, for example, a naphthyl, indolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, quinolinyl or isoquinolinyl unit or a partially or completely hydrogenated analogue thereof. Particularly preferably, the additional substituent on the nitrogen atom of the  $\beta$ -amino group is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl,

M 17·02·00


- 32 -




(a1)




(a2)




(a3)




(a4)




(a5)




(a6)




(a7)




(a8)




(a9)




(a10)




(a11)




(a12)



(a13)




(a14)



(a15)

M 17-02-00

- 33 -



The residue derived from a  $\beta$ -amino acid is bonded to one of the two central phenylene units which are bonded via a linker group L, and that phenylene unit will here be referred to as phenylene unit A. Apart from the residue derived from a  $\beta$ -amino acid and the linker group L, preferably the phenylene unit A carries no further substituents, but can contain one or more residues which are selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom. The alkyl residue(s) are preferably  $C_{1-6}$ -alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl. The cycloalkyl residue(s) are preferably  $C_{3-7}$ -cycloalkyl residues such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. The alkoxy residue(s) are preferably  $C_{1-6}$ -alkoxy residues such as methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, and the halogen atom(s) are preferably F, Cl, Br or I.

M 17-02-00

The phenylene unit A is bonded to a second central phenylene unit, which will here be referred to as phenylene unit B, via a linker group L. In addition to the linker group L, the phenylene unit B carries a further substituent which is selected from the group consisting of a guanidine, urea or thiourea unit which is optionally incorporated into a cyclic ring system. Moreover, the phenylene unit B preferably carries no further substituents, but can contain one or more residues which are selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom. The alkyl residue(s) are preferably C<sub>1-6</sub>-alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl. The cycloalkyl residue(s) are preferably C<sub>3-7</sub>-cycloalkyl residues such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. The alkoxy residue(s) are preferably C<sub>1-6</sub>-alkoxy residues such as methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, and the halogen atom(s) are preferably F, Cl, Br or I.

The two central phenylene units can be 1,3- or 1,4-linked with respect to the linker group L and the residue derived from a β-amino acid or the guanidine, urea or thiourea unit, i.e. the residue derived from a β-amino acid and the linker group L can be substituted on the phenylene unit A in the meta- or para-position to one another, and at the same time the linker group L and the guanidine, urea or thiourea unit on the phenylene unit B can be substituted in the meta- or para-position to one another, where each combination of the abovementioned substitution patterns is possible for the central phenylene A-linker L-phenylene B unit of the compounds according to the invention. According to the present invention, compounds are particularly preferred whose central phenylene A-linker L-phenylene B unit according to the above definition consists of a p-substituted phenylene unit A and a p-substituted phenylene unit B, a p-substituted phenylene unit A and an m-substituted phenylene unit B, an m-substituted phenylene unit A and a p-substituted phenylene unit B or an m-substituted phenylene unit A and an m-substituted phenylene unit B. According to the present invention, compounds are particularly preferred whose central phenylene

M 17.02.00

A-linker L-phenylene B unit according to the above definition consists of an m-substituted phenylene unit A and an m-substituted phenylene unit B.

According to the present invention, the linker group L is selected from the group which consists of the elements -(CH<sub>2</sub>)<sub>m</sub>NHSO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NH(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>NHCO(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>CONH(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>OCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>COO(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>OOC(CH<sub>2</sub>)<sub>n</sub>-, (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>CO(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>COCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, -NHCONH-, -(CH<sub>2</sub>)<sub>m</sub>SCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>S(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>SOCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, 10 -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- or -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>-, where m and n in each case are an integer of 0 or 1 and m + n is ≤ 1.


According to the invention, the linker group L is preferably -NHSO<sub>2</sub>-, -CH<sub>2</sub>NHSO<sub>2</sub>-, -NHSO<sub>2</sub>CH<sub>2</sub>-, -SO<sub>2</sub>NH-, -CH<sub>2</sub>SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCH<sub>2</sub>-, -NHCO-, -CH<sub>2</sub>NHCO-, -NHCOCH<sub>2</sub>-, -CONH-, -CH<sub>2</sub>CONH-, -CONHCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-, -CH<sub>2</sub>CH<sub>2</sub>O-, -COO-, -CH<sub>2</sub>COO-, -COOCH<sub>2</sub>-, -OOC-, -OOCCH<sub>2</sub>-, -CH<sub>2</sub>OOC-, -CH<sub>2</sub>CO-, -COCH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CO-, -COCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>COCH<sub>2</sub>-, -NHCONH-, -SCH<sub>2</sub>-, -CH<sub>2</sub>S-, -CH<sub>2</sub>SCH<sub>2</sub>, -SCH<sub>2</sub>CH<sub>2</sub>-, CH<sub>2</sub>CH<sub>2</sub>S-, -SOCH<sub>2</sub>-, -CH<sub>2</sub>SO-, -CH<sub>2</sub>SOCH<sub>2</sub>-, -SOCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO-, -SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>-, 15 -CH<sub>2</sub>SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-. Particularly preferred linker groups L here are -NHSO<sub>2</sub>-, -CH<sub>2</sub>NHSO<sub>2</sub>-, -NHSO<sub>2</sub>CH<sub>2</sub>-, -SO<sub>2</sub>NH-, -CH<sub>2</sub>SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCH<sub>2</sub>-, -NHCO-, -CH<sub>2</sub>NHCO-, -NHCOCH<sub>2</sub>-, -CONH-, -CH<sub>2</sub>CONH-, -CONHCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-, -CH<sub>2</sub>CH<sub>2</sub>O-, -COO-, -CH<sub>2</sub>COO-, -COOCH<sub>2</sub>-, -OOC-, -OOCCH<sub>2</sub>-, -CH<sub>2</sub>OOC-, -CH<sub>2</sub>CO-, -COCH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CO-, -COCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>COCH<sub>2</sub>-, -NHCONH-, -SCH<sub>2</sub>-, -CH<sub>2</sub>S-, -CH<sub>2</sub>SCH<sub>2</sub>, -SCH<sub>2</sub>CH<sub>2</sub>-, CH<sub>2</sub>CH<sub>2</sub>S-, -SOCH<sub>2</sub>-, -CH<sub>2</sub>SO-, -CH<sub>2</sub>SOCH<sub>2</sub>-, -SOCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO-, -SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>-, 20 -CH<sub>2</sub>SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-.

25 The central phenylene unit B carries as a substituent a residue which is selected from the group consisting of a guanidine, urea or thiourea unit. This guanidine, urea or thiourea unit can either be open-chained or a constituent of a cyclic system. The two nitrogen atoms of the respective unit, which are only bonded via single bonds, can carry additional substituents R<sup>6</sup>, R<sup>8</sup> and R<sup>9</sup>. These substituents can independently of one another or simultaneously be hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or

unsaturated, optionally substituted heterocyclic residue or can be bonded to one another and can thus form a heterocyclic ring system together with the nitrogen atom(s) to which they are bonded. In this context, preferred substituents are selected from the group consisting of hydrogen, a C<sub>1-6</sub>-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl, a C<sub>3-7</sub>-cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, an aryl such as, for example, phenyl, benzyl or tolyl, a heterocyclic residue such as, for example, pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazole, benzofuran, benzoxazole, benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine and can alternatively be substituted by one or more C<sub>1-6</sub>-alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl, C<sub>3-7</sub>-cycloalkyl residues such as cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or cyclohexyl, aryl residues such as phenyl, benzyl, tolyl, naphthyl, indolyl, heterocyclic residues such as pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazole, benzofuran, benzoxazole, benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine, or functional groups such as a double bond to a heteroatom such as oxygen, sulphur or nitrogen, an optionally substituted amino group, a nitro group, a halogen, a hydroxyl group, an ether group, a sulphide group, a mercaptan group, a cyano group, an isonitrile group, an alkenyl group, an alkinyl group, an aldehyde group, a keto group, a carboxyl group, an ester group, an amide group, a sulphoxide group or a sulphone group. One or more additionally saturated or unsaturated rings can furthermore be fused to the abovementioned cyclic residues with formation of, for example, a naphthyl, indolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, quinolinyl or

isoquinolinyl unit or a partially or completely hydrogenated analogue thereof. Particularly preferred are substituents such as hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-methylcyclohexyl, 5,5-dimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl or one of the abovementioned residues (a1) to (a28).

10 The two residues R<sup>8</sup> and R<sup>9</sup> on the terminal nitrogen atom of the corresponding guanidine, urea or thiourea unit can be bonded to one another and thus, with the nitrogen atom, form a heterocyclic system which can be selected, for example, from the following, non-conclusive list:























15 where the ring systems shown can carry one or more residues which are selected from the group consisting of hydrogen, a C<sub>1-6</sub>-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or

11702-00

hexyl, a C<sub>3-7</sub>-cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or cyclohexyl, an aryl such as, for example, phenyl, benzyl or tolyl, a heterocyclic residue such as, for example, pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazole, benzofuran, benzoxazole, benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine, or a terminal or internal E or Z alkene unit, and can alternatively be substituted by one or more C<sub>1-6</sub>-alkyl residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl or hexyl, C<sub>3-7</sub>-cycloalkyl residues such as cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or cyclohexyl, aryl residues such as phenyl, benzyl, tolyl, naphthyl, indolyl, heterocyclic residues such as pyrrolidine, piperidine, piperazine, pyrrole, pyridine, tetrahydrofuran, furan, thiophene, tetrahydrothiophene, imidazolidine, imidazole, oxazolidine, oxazole, thiazolidine, thiazole, thioxazole, benzofuran, benzoxazole, benzothiazole, benzimidazole, quinoline, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, triazole, tetrazole, pyrimidine, purine, cytosine, thymine, uracil, adenine, guanine or xanthine, or functional groups such as a double bond to a heteroatom such as oxygen, sulphur or nitrogen, an optionally substituted amino group, a nitro group, a halogen, a hydroxyl group, an ether group, a sulphide group, a mercaptan group, a cyano group, an isonitrile group, an alkenyl group, an alkinyl group, an aldehyde group, a keto group, a carboxyl group, an ester group, an amide group, a sulphoxide group or a sulphone group. One or more additionally saturated or unsaturated rings can furthermore be fused to the above-mentioned cyclic residues with formation of, for example, a naphthyl, indolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, quinolinyl or isoquinolinyl unit or a partially or completely hydrogenated analogue thereof.

30 Of the ring systems shown above, the four- to six-membered ring systems are preferred.

As mentioned above, the urea, thiourea or guanidine unit can be open-chained or incorporated into a cyclic system and can thus be a constituent of one of the following preferred functional units:



where the above list is not a conclusive enumeration of all possible structural units.

10

According to the invention, in addition to the abovementioned preferred structural units, their analogues are also included in which one or more 4- to 6-membered ring

M 17.02.00

- 40 -

systems are fused to the heterocycle, such as, for example, the corresponding benzo-fused analogues of the abovementioned structural units.

In the structural units shown above, R<sup>6</sup>, R<sup>8</sup> and R<sup>9</sup> are as defined above.

5

Furthermore, in the above structural units R<sup>7</sup> can be absent, or can be hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue such as, for example, a C<sub>1-6</sub>-alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl or a C<sub>3-7</sub>-cycloalkyl such as cyclopropyl, cyclobutyl,

10 cyclopentyl, cyclohexyl, -NO<sub>2</sub>, -CN, -COR<sup>7</sup> or -COOR<sup>7</sup>, where R<sup>7</sup> can be hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue, which can be saturated or unsaturated and/or can contain further heteroatoms, and is preferably a C<sub>1-6</sub>-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, a C<sub>3-7</sub>-cycloalkyl such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, an aryl such as, for example, phenyl, benzyl, tolyl, or a substituted derivative thereof.

20

Particularly preferred compounds of the formula (1) according to the invention are those in which the amino group included in the residue derived from a  $\alpha$ -amino acid carries a residue -SO<sub>2</sub>R<sup>4</sup>, where R<sup>4</sup> is preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-

methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)-aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methylbenzothiazole-2-yl, N-methoxycarbonylpiperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl, the linker group L is - $\text{NHSO}_2-$ , - $\text{CH}_2\text{NSO}_2-$ , - $\text{NHSO}_2\text{CH}_2-$ , and the residue located on the phenylene unit is an open-chain or cyclic guanidine unit, where a cyclic guanidine unit such as, for example, a 4,5-dihydro-1H-imidazol-2-yl-amino unit is particularly preferred.

Furthermore, particularly preferred compounds of the formula (1) according to the present invention are those in which the amino group included in the residue derived from a  $\beta$ -amino acid carries a residue  $-\text{SO}_2\text{R}^4$ , where  $\text{R}^4$  is preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof,  $-\text{C}_6\text{H}_2(\text{CH}_3)_3$ ,  $-\text{C}_6(\text{CH}_3)_5$ ,  $-\text{CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)camphor-10-yl, (R)(-)camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methyl-

phenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-aryl-sulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl, the linker group L is -NHCO-, -CH<sub>2</sub>NHCO-, -NHCOC<sub>2</sub>- or -OCH<sub>2</sub>-, -CH<sub>2</sub>O-, -CH<sub>2</sub>OCH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>-, and the residue located on the phenylene unit is an open-chain or cyclic guanidine unit, where a cyclic guanidine unit such as, for example, a 4,5-dihydro-1H-imidazol-2-yl-amino unit is particularly preferred.

Moreover, particularly preferred compounds of the formula (1) according to the present invention are those in which the amino group included in the residue derived from a  $\beta$ -amino acid carries a residue -COR<sup>4</sup>, where R<sup>4</sup> is preferably hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)camphor-10-yl, (R)(-)camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methoxyphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphon-

ylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolizin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl, the linker group L is -NHSO<sub>2</sub>-, -CH<sub>2</sub>NHSO<sub>2</sub>-, -NHSO<sub>2</sub>CH<sub>2</sub>, and the residue located on the phenylene unit is an open-chain or cyclic guanidine unit, where a cyclic guanidine unit such as, for example, a 4,5-dihydro-1H-imidazol-2-yl-amino unit is particularly preferred.


10

The present invention comprises both the individual enantiomers or diastereomers and the corresponding racemates, diastereomer mixtures and salts of the compounds defined in Claim 1. In addition, according to the present invention all possible tautomeric forms of the compounds described above are also included. The present invention furthermore comprises the pure E and Z isomers of the compounds of the general formula (1) and their E/Z mixtures in all ratios. The diastereomer mixtures or E/Z mixtures can be separated into the individual isomers by chromatographic procedures. The racemates can be separated into the respective enantiomers either by chromatographic procedures on chiral phases or by resolution.

15

20 The compounds described above can be prepared from commercially available starting compounds. The main steps of the preparation process according to the invention are the reaction of a β-amino acid of the formula (2)

25




where

P is  $-(CH_2)_mNO_2$ ,  $-(CH_2)_mO-C_{1-6}$ -alkyl,  $-(CH_2)_mSO_2P'$ ,  $-(CH_2)_mCOP'$ ,  $-(CH_2)_mCH_2O-C_{1-6}$ -alkyl, where m in each case is an integer of 0 or 1; P' is  $-OH$ ,  $-O-C_{1-6}$ -alkyl, and the other residues are as defined above;


5

with a compound  $R^4-A$  to give a compound of the formula (3),




where

- 10  $R^4$  is  $-SO_2R^4'$ ,  $-COOR^{4''}$ , or  $-COR^4$ ;  $R^4'$  and  $R^{4''}$  are as defined above; A is  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O$ -triflyl,  $-O$ -tosyl,  $-O-C_{1-6}$ -alkyl,  $-O-CO-C_{1-6}$ -alkyl,  $-O-CO-O-C_{1-6}$ -alkyl,  $-OC(CH_3)=CH_2$ ; and the other residues are as defined above;  
the conversion of the residue P into the residue Q, where Q is  $-(CH_2)_mNH_2$ ,  $-(CH_2)_mOH$ ,  $-(CH_2)_mCH_2OH$ ,  $-(CH_2)_mSO_2A$ ,  $-(CH_2)_mCOA$ , A is as defined above; m is an integer of 0 or 1;
- 15 the reaction of the compound (3) obtained above with a compound of the formula (4)




- 20 where S is  $ASO_2(CH_2)_n-$ ,  $NH_2(CH_2)_n-$ ,  $ACO(CH_2)_n-$ ,  $HOCH_2(CH_2)_n-$ ,  $M(CH_2)_n-$ ,  $MCH_2(CH_2)_n-$ ,  $HSCH_2(CH_2)_n-$  or  $HS(CH_2)_n-$ , where n is an integer of 0 or 1; M is a residue including Mg, Li, Cd or Sn; A is as defined above; and

17.02.00

C is  $\text{-NO}_2$  orX, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> are as defined above;

to give a compound of the formula (5)



where the residues are as defined above;


if appropriate the conversion of C, if C is a nitro group, into an optionally cyclic urea, thiourea or guanidine unit with obtainment of the compound (1); and

10 if appropriate the removal of protective groups and/or derivatization of nitrogen atoms, which are present, at preferred times within the preparation process, and/or conversion of the compound obtained into the free acid and/or conversion of the compound obtained into one of its physiologically acceptable salts by reaction with an inorganic or organic base or acid.

15 The  $\beta$ -amino acid derivatives of the formula (2) are either commercially available or are accessible in a simple manner by standard chemical processes, such as are known to any person skilled in the art and described in standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme-Verlag, Stuttgart. In particular, reference is made to the preparation process for  $\beta$ -amino acid derivatives described by Rodionow et al., J. Am. Chem. Soc. 51, 1929, 844-846, Kunz et al., Angew. Chem. 101, 1989, 1042-1043 and Ishihara et al., Bull. Chem. Soc. Jpn., 68, 6, 1995, 1721-1730.

M 1702-00

According to a preferred embodiment of the present invention, the  $\beta$ -amino acid derivatives of the formula (2) are obtained by reaction of malonic acid with a benzaldehyde derivative of the formula (2a)



5

where  $R^{10}$  and P are as defined above, in the presence of ammonia, ammonium compounds or amines. Instead of malonic acid, an ester can also be used, if appropriate with addition of a base conventionally employed for these purposes, such as NaH or a sodium alkoxide, preferably sodium methoxide or sodium ethoxide. An ammonium compound such as, for example, ammonium acetate is preferably employed as the nitrogen compound.

10  
15

The benzaldehyde derivatives (2a) are either commercially available or are accessible in a simple manner by standard chemical processes, such as are known to any person skilled in the art and described in standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme-Verlag, Stuttgart.

20

According to a preferred embodiment of the present invention, the compound of the formula (2a) employed is a nitrobenzaldehyde derivative such as 3- or 4-nitrobenzaldehyde or an alkoxybenzaldehyde derivative such as 3- or 4-methoxybenzaldehyde.

25

According to a preferred embodiment of the present invention, the  $\beta$ -amino acid of the formula (2) is obtained by reaction of approximately equimolar amounts of malonic acid, ammonium acetate and 3-nitrobenzaldehyde or 3-methoxybenzaldehyde in a solvent such as isopropanol with heating at 50 to 110°C for several

hours, preferably 2 to 6 hours, preferably under reflux of the solvent, in the surrounding atmosphere (i.e. in the air and under normal pressure).

For the following reaction steps, the carboxyl group is blocked by a conventional protective group P. Protective groups of this type are known to the person skilled in the art and do not expressly need to be mentioned here. Particularly preferably, the carboxyl group is esterified, P being a C<sub>1-6</sub>-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, a C<sub>3-7</sub>-cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, an aryl such as, for example, phenyl, benzyl or tolyl or a substituted derivative thereof. Furthermore, the preparation process according to the invention for the compounds of the general formula (1) can be carried out on a solid phase. In this case the carboxyl residue can be bonded to any solid phase conventionally used for reactions of this type, such as a polystyrene resin, for example a Wang polystyrene resin.

According to a preferred embodiment according to the invention, the carboxyl group of the above β-amino acid is esterified by reaction with an alcohol such as ethanol. This can be carried out under conditions known to the person skilled in the art, such as acid catalysis and, if appropriate, addition of a dehydrating agent such as dicyclohexylcarbodiimide. Preferably, however, the β-amino acid is suspended in the appropriate alcohol, such as ethanol, which is present in excess, HCl is passed in over a period of approximately 30 minutes to approximately 2 hours and the mixture is then heated in a surrounding atmosphere for several hours, preferably approximately 1 to 6 hours and particularly preferably approximately 3 to 5 hours, at approximately 50 to approximately 100°C, preferably under reflux of the alcohol.

The carboxyl-protected β-amino acids thus accessible are reacted with a suitable sulphonylating, carbamoylating or acylating reagent in order to obtain the corresponding sulphonamide, carbamate or amide derivatives. The sulphonating reagent preferably used is a sulphonyl chloride of the formula R<sup>4-</sup>-SO<sub>2</sub>Cl or a

carbamoyl chloride of the formula R<sup>4</sup>-OCOCl, where R<sup>4</sup> is a C<sub>1-10</sub>-alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or camphor-10-yl, an aryl such as phenyl, benzyl, tolyl, mesityl or substituted derivatives of these such as -C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methylthiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl, 5-methyl-isoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl, 8-quinolinyl, or a heterocyclic analogue of the abovementioned cyclic residues. Instead of the abovementioned sulphonyl or carbamoyl chlorides, the corresponding fluorides, bromides or iodides can also be employed. As an acylating reagent, the appropriate carbonyl halides or carboxylic anhydrides are reacted with the amino group, where the appropriate C<sub>1-6</sub>-alkyl chlorides such as methyl chloride, ethyl chloride, propyl chloride, isopropyl chloride, butyl chloride, isobutyl chloride, t-butyl chloride, pentyl chloride, isopentyl chloride, neopentyl chloride, hexyl chloride, C<sub>3-7</sub>-cycloalkyl chlorides such as cyclopropyl chloride, cyclobutyl chloride, cyclopentyl chloride, cyclohexyl chloride, aryl chlorides such as phenyl chloride,

M 17.02.00

- 49 -

benzyl chloride, tolylcarboxylic acid chlorides or substituted derivatives thereof are preferred according to the invention. For the preparation of the urea or thiourea derivatives, the amino group is preferably first reacted with a carbonic acid or thiocarbonic acid derivative such as a chloroformic acid ester or thiophosgene and then with a desired amine. The above reactions and their implementation are well known to the person skilled in the art and described in detail in standard works such as, for example, Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart.

- 10 According to a preferred embodiment of the invention, the carboxyl-protected  $\beta$ -amino acid of the formula (2) is treated with an equimolar amount or a slight excess of the appropriate sulphonylating agent, for example phenylsulphonyl chloride, or acylating agent, for example mesitylacetyl chloride, with cooling, preferably at 0°C, in a solvent such as pyridine or dioxane in a surrounding atmosphere in the presence of a base such as an amine, preferably triethylamine or diisopropylethylamine, and stirred at this temperature for a period of approximately 10 minutes to approximately 2 hours. In the case of sulphonylation, stirring at room temperature for several hours, preferably approximately 2 to 6 hours, follows this.
- 15 Before the construction of the linker group L, the residue P of the compound of the formula (3) must be converted into a group Q which can participate in a nucleophilic substitution either as a nucleophilic reagent or as a substrate. If P includes a nitro group, this is reduced to the corresponding amino group, which reduction can be carried out according to the present invention preferably by addition of tin-(II) chloride to a solution of the compound of the formula (3) in a solvent such as ethanol and subsequent heating to approximately 50 to 110°C, preferably under reflux of the solvent, for several hours, preferably approximately 1 to 4 hours, in a surrounding atmosphere. If P includes an ether group, the liberation of the corresponding hydroxyl group is preferably carried out by addition of a Lewis acid such as boron tribromide in a solvent such as dichloromethane with cooling, preferably at -78°C, and subsequent stirring for several hours, preferably 6 to 24 hours, at room
- 20
- 25
- 30


M 17.02.00

- 50 -

temperature. If P includes a sulphonic acid or carboxylic acid group, conversion into the corresponding sulphonyl or carbonyl halide preferably takes place. This can be carried out in a manner known to the person skilled in the art, for example by reaction of the corresponding sulphonic or carboxylic acid with thionyl chloride.

5

The compound prepared in this way is then reacted with a compound of the formula (4)




where

10      S        is  $\text{ASO}_2(\text{CH}_2)_n-$ ,  $\text{NH}_2(\text{CH}_2)_n-$ ,  $\text{ACO}(\text{CH}_2)_n-$ ,  $\text{HOCH}_2(\text{CH}_2)_n-$ ,  
 $\text{M}(\text{CH}_2)_n-$ ,  $\text{MCH}_2(\text{CH}_2)_n-$ ,  $\text{HSCH}_2(\text{CH}_2)_n-$  or  $\text{HS}(\text{CH}_2)_n-$ , where  
 n is an integer of 0 or 1;

M        is a residue including Mg, Li, Cd or Sn;


A        is as defined above; and

C        is  $-\text{NO}_2$  or



15      X, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> are as defined above;

to give a compound of the formula (5)



20      where the residues are as defined above. This reaction formally represents the substitution of a leaving group in one of the starting compounds by a nucleophilic unit in the other starting compound in each case.

M 17-02-00

- 51 -

- According to a preferred embodiment of the present invention, the reactants are mixed together in approximately equimolar amounts in the presence of a base such as pyridine or sodium hydride and optionally in a solvent such as, for example, tetrahydrofuran (THF) or dimethylformamide (DMF) in a surrounding atmosphere at room temperature or with cooling, preferably at approximately 0°C, and stirred for several hours, preferably approximately 1 h to approximately 24 hours, at room temperature or with cooling, for example at 0°C.
- The compounds of the formula (5) thus obtained are converted into the compounds of the formula (1) according to the invention by conversion of the terminal nitro group into an open-chain or cyclic guanidine, urea or thiourea unit.
- For this purpose, the nitro group is first preferably converted according to the invention into an amino group by addition of a customary reducing agent such as tin-(II) chloride, if appropriate in the presence of solvents such as ethanol, by stirring the reaction mixture with heating to approximately 50 to 110°C, preferably under reflux of the solvent, in a surrounding atmosphere for approximately 2 hours.
- The amino group thus obtained is then converted into a guanidine, urea or thiourea unit. For this purpose, the above amino group is preferably first reacted with a carbonic acid ester or thiocarbonic acid ester derivative in a solvent such as dimethylformamide (DMF) in the presence of mercury-(II) chloride with cooling, preferably at approximately 0°C, and stirring for approximately 10 minutes for up to approximately 3 hours with cooling, preferably at approximately 0°C, and if appropriate then at room temperature. The carbonic acid ester or thiocarbonic acid ester derivative employed can preferably be phosgene, triphosgene, thiophosgene, chloroformic acid esters or thiopseudourea derivatives, commercially available chloroformic acid esters being preferred for the preparation of the urca derivatives, thiophosgene being preferred for the preparation of the thiourea derivatives and thiopseudourea derivatives being preferred for the preparation of the guanidine

M 17-02-00

derivatives.

The carbamates or isothiocyanates formed in this way can be converted into the corresponding urea, thiourea and guanidine derivatives by reaction with appropriate amines. Amines which can be used are substances of the formula HNRR', where R and R' independently of one another or simultaneously are hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an alkylamine residue, an alkylamide residue or are bonded to one another and together with the nitrogen atom can form an optionally substituted heterocyclic ring system which can be saturated or unsaturated and/or can contain further heteroatoms. With respect to the preferred residues on the amine, reference is made to the above description of the compounds according to the invention. According to the invention, the carbamate or isothiocyanate is preferably reacted with an amine at room temperature with stirring for approximately 1 to 5 hours, preferably approximately 2 to 3 hours, in the presence of an auxiliary base such as diisopropylethylamine in a solvent such as dimethylformamide (DMF). In the case of the preparation of cyclic guanidine derivatives, the corresponding isothiocyanate is preferably first heated in ethanol for several hours, preferably approximately 12 to 24 hours, and then heated with a diamine such as diaminoethane in a solvent such as toluene, dimethylformamide (DMF) or a mixture of the two.

According to a further preferred embodiment of the present invention, it is also possible to generate the above guanidine, urea or thiourea group in the above manner initially on the compound of the formula (4) and to react the compound of the formula (4) thus obtained subsequently in the manner described above with the compound of the formula (3).

The compounds obtained according to the processes explained above can furthermore be derivatized by removal of protective groups which may be present, continued substitution of nitrogen atoms, which are present, at preferred positions in the

M 17.02.00

- 53 -

preparation process, and/or conversion of the compound obtained into the free acid and/or its physiologically acceptable salts. For example, the t-butoxymethoxy-carbonyl groups conventionally used as a protective group for nitrogen atoms are removed in an acidic medium, for example by addition of trifluoroacetic acid.

5 Possible alkylating agents for the derivatization of nitrogen atoms are reagents conventionally used for this purpose in this step, with which, for example, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue can be bonded to the appropriate nitrogen atom. With respect to the substituents

10 preferably bonded to the respective nitrogen atoms, reference is made to the above description of the compounds according to the invention. The above reactions and their implementation are well known to the person skilled in the art and described in detail in standard works such as, for example, Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag,

15 Stuttgart.

The ester derivatives according to the invention can be converted into the corresponding free carboxylic acids in a customary manner, such as, for example, by basic ester hydrolysis.

20 If desired, the compounds according to the invention can be converted into their physiologically acceptable salts. This can be effected either by reaction with an organic or inorganic base such as, for example, an alkali metal hydroxide or alkaline earth metal hydroxide such as KOH, NaOH, LiOH, Mg(OH)<sub>2</sub> or Ca(OH)<sub>2</sub>, as a result of which the terminal carboxyl group is deprotonated and the corresponding carboxylate is formed, or by reaction with an organic or inorganic acid such as, for example, hydrochloric acid, sulphuric acid, phosphoric acid, mandelic acid, oleic acid, linoleic acid or p-toluenesulphonic acid, as a result of which one or more of the nitrogen atoms present are protonated.

30

M 17:02:00

The steps of the preparation process according to the invention described above can be carried out in a normal atmosphere, i.e. in air, and without the use of absolute, i.e. essentially anhydrous, solvents.

5      The compounds according to the invention exhibit a very good antagonistic action against integrin receptors, in particular the  $\alpha_v\beta_3$  receptor or the  $\alpha_v\beta_5$  receptor. This makes them suitable for use as pharmaceutical compositions, in particular for the treatment and prophylaxis of arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis, cancer and ophthalmic diseases.

10     The compounds according to the invention can be used as active compound components for the production of pharmaceutical compositions against the abovementioned diseases. For this purpose, they can be converted into the customary formulations such as tablets, coated tablets, aerosols, pills, granules, syrups, emulsions, suspensions and solutions using inert, non-toxic, pharmaceutically suitable excipients or solvents. The compounds according to the invention are preferably used here in such an amount that their concentration in the total mixture is approximately 0.5 to approximately 90% by weight, the concentration being dependent, *inter alia*, on the corresponding indication of the pharmaceutical composition.

15     The abovementioned formulations are prepared, for example, by extending the active compounds using solvents and/or excipients having the above properties, where, if appropriate, emulsifying agents or dispersing agents, and, in the case of water as a solvent, alternatively an organic solvent additionally has to be added.

20     The pharmaceutical compositions according to the invention can be administered in a customary manner.

25     The present invention is illustrated below with the aid of non-restricting examples and comparison examples.


M 17-02-00

- 55 -

### Examples

In the examples below, all quantitative data relate, unless stated otherwise, to percentages by weight. The mass determinations were carried out by high-performance liquid chromatography-mass spectrometry (HPLC-MS) using the electron spray ionization (ESI) method.

卷之三

Example 1:*General synthesis scheme:*

5

- a) 2-propanol, reflux; b) HCl, ethanol; c) PhSO<sub>2</sub>Cl, Et<sub>3</sub>N; d) SnCl<sub>2</sub>, ethanol; e) 3-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl; f) SnCl<sub>2</sub>, ethanol; g) HgCl<sub>2</sub>, 1,3-bis(tert-butyloxycarbonyl)-2-methyl-2-thiopseudourea; h) TFA, dichloromethane, i) LiOH.

*3-Amino-3-(3-nitrophenyl)-propionic acid hydrochloride (1a)*

151 g of 3-nitrobenzaldehyde, 94 g of ammonium acetate and 127 g of malonic acid were heated under reflux for 5 h in 1 l of isopropanol. The solution was filtered and  
5 the precipitate was washed with 0.7 l of hot isopropanol. The crude product was dried in vacuo, suspended in 1.5 l of water, treated with hydrochloric acid and filtered, and the filtrate was concentrated (yield: 146 g).

10           <sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 3.09 (m, 2 H), 4.88 (m, 1 H), 7.74 (t, 1 H), 7.90 (d, 1 H), 8.33 (d, 1 H), 8.43 (s, 1 H).

*Ethyl 3-amino-3-(3-nitrophenyl)-propionate hydrochloride (1b)*

15           60 g of (1a) were suspended in 660 ml of ethanol, and gaseous HCl was passed in for 1 h. The reaction mixture was then heated under reflux for 4 h and then cooled and concentrated. 62 g of a white solid were obtained.

20           <sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 1.22 (t, 3 H), 3.12 (dd, 1 H), 3.20 (dd, 1 H), 4.18 (q, 2 H), 4.95 (t, 1 H), 7.77 (t, 1 H), 7.94 (d, 1 H), 8.35 (d, 1 H), 8.43 (s, 1 H).

*Ethyl 3-benzenesulphonylamino-3-(3-nitrophenyl)-propionate (1c)*

25           8.1 g of phenylsulphonyl chloride were added at 0°C to a solution of 10 g of (1b) in 100 ml of pyridine. After a reaction time of 15 min, 6.3 ml of triethylamine were added and the mixture was stirred at room temperature. After 5 h, it was concentrated, treated with 1 N HCl, extracted with dichloromethane, dried over MgSO<sub>4</sub> and concentrated. Chromatographic purification (dichloromethane/methanol = 5:1) yielded 11.4 g of a white solid.

30           <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.16 (t, 3 H), 2.80 (m, 2 H), 4.05 (q, 2 H), 4.87 (q, 1 H), 6.06 (d, 1 H), 7.35-7.50 (m, 5 H), 7.71 (d, 2 H), 7.92 (s, 1 H), 8.03 (d, 1 H).

M 17.02.00

- 58 -

*Ethyl 3-(3-aminophenyl)-3-benzenesulphonylamino-propionate (1d)*

4.77 g of tin-(II) chloride were added to a solution of 2.0 g of (1c) in 60 ml of ethanol, and the reaction mixture was heated under reflux for 2 h. After cooling, the  
5 solution was hydrolysed by pouring it onto ice and adjusted to pH = 8 using an NaHCO<sub>3</sub> solution (5%). It was then extracted with dichloromethane and the organic phase was washed with NaCl, dried over MgSO<sub>4</sub> and concentrated. 1.79 g of a yellow oil were obtained.

10      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.14 (t, 3 H), 2.72 (dd, 1 H), 2.81 (dd, 1 H), 4.02 (q, 2 H), 4.65 (q, 1 H), 5.66 (d, 1 H), 6.41 (m, 1 H), 6.48 (m, 2 H), 6.96 (t, 1 H), 7.40 (m, 2 H), 7.50 (m, 1 H), 7.75 (m, 2 H).

15      *Ethyl 3-benzenesulphonylamino-3-(3-[3-nitrophenylsulphonylamino]-phenyl)-propionate (1e)*

382 mg of 3-nitrobenzenesulphonyl chloride were added at 0°C to a solution of 500 mg of (1d) in 4 ml of pyridine. After a reaction time of 1 h at 0°C and 2 h at room temperature, the mixture was concentrated, treated with 1 N HCl and extracted with dichloromethane. After drying over MgSO<sub>4</sub>, the solvent was removed and 20 649 mg of a solid were obtained.

25      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.02 (t, 3 H), 2.50 (dd, 1 H), 2.59 (dd, 1 H), 3.88 (q, 2 H), 4.52 (q, 1 H), 5.70 (d, 1 H), 6.49 (s, 1 H), 6.82-6.90 (m, 3 H), 7.06 (t, 1 H), 7.34 (t, 2 H), 7.44 (t, 1 H), 7.59 (t, 1 H), 7.64 (d, 2 H), 7.96 (d, 1 H), 8.31 (d, 1 H), 8.49 (m, 1 H).

30      *Ethyl 3-(3-[3-aminophenylsulphonylamido]-phenyl)-3-benzenesulphonylamino-propionate (1f)*

M 1702.00

1.27 g of tin-(II) chloride were added to a solution of 600 mg of (1e) in 9 ml of ethanol, and the reaction mixture was heated under reflux for 2 h. After cooling, the solution was hydrolysed by pouring it onto ice and adjusted to pH = 8 using an NaHCO<sub>3</sub> solution (5%). It was then extracted with dichloromethane, and the organic phase was washed with NaCl, dried over MgSO<sub>4</sub> and concentrated. 394 mg of a yellow, viscous residue were obtained.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.14 (t, 3 H), 2.65 (dd, 1 H), 2.73 (dd, 1 H), 4.01 (q, 2 H), 4.63 (q, 1 H), 5.81 (d, 1 H), 6.32 (s, 1 H), 6.79 (d, 2 H), 6.88 (d, 1 H), 6.99 (t, 1 H), 7.05-7.14 (m, 3 H), 7.22 (t, 1 H), 7.39 (m, 2 H), 7.51 (t, 1 H), 7.71 (d, 2 H).

*Ethyl 3-benzenesulphonylamino-3-(3-(3-[N,N'-bis-t-butoxycarbonyl-guanidino]-phenylsulphonylamino)-phenyl)-propionate (1g)*

15 0.16 ml of triethylamine, 195 mg of 1,3-bis(t-butoxycarbonyl)-2-methyl-2-thio-pseudourea and 132 mg of mercuric chloride were added at 0°C to a solution of 281 mg of (1f) in 10 ml of DMF. After a reaction time of 30 min at 0°C, the mixture was stirred at room temperature for a further 1.5 h. 15 ml of ethyl acetate were added, and the mixture was stirred for 30 minutes before the precipitate was filtered off. The solution was concentrated and reused without purification.

20  
25 <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.12 (t, 3 H), 1.52 (s, 9 H), 1.54 (s, 9 H), 2.65 (dd, 1 H), 2.72 (dd, 1 H), 3.99 (q, 2 H), 4.66 (m, 1 H), 5.78 (m, 1 H), 6.72 (m, 1 H), 6.85 (d, 1 H), 6.96-7.07 (m, 3 H), 7.33-7.49 (m, 5 H), 7.65 (d, 2 H), 7.78 (m, 1 H), 8.12 (s, 1 H).

M 17-02-00

- 60 -

*Ethyl 3-benzenesulphonylamino-3-(3-[3-guanidinophenylsulphonylamino]-phenyl)-propionate (1h)*

2 ml of trifluoroacetic acid were added to a solution of 246 mg of (1g) in 2 ml of  
5 methylene chloride. The reaction was stirred at room temperature for 4 h and the solvent was then removed on a rotary evaporator. 100 mg of a viscous oil were obtained by means of chromatographic purification (dichloromethane/methanol 1:1).

Mass spectrometry: 546(MH<sup>+</sup>)

10

*3-Benzenesulphonylamino-3-[3-(3-guanidino-benzenesulphonylamino)-phenyl]-3-propionic acid, trifluoroacetic acid salt (1):*


98 mg of lithium hydroxide monohydrate were added to a solution of 98 mg of (1h)  
15 in 14 ml of water, and the reaction mixture was stirred at room temperature for 70 h. The solution was acidified to pH = 2 using trifluoroacetic acid and concentrated. The crude product was purified by RP chromatography (RP 18 water/acetonitrile). 42 mg of a white solid were obtained.

20 Elemental analysis for C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>11</sub>S<sub>2</sub> × 2.0 TFA × 2.0 H<sub>2</sub>O:

calculated:	C 39.95;	H 3.74;	N 8.96
found:	C 39.7;	H 3.7;	N 9.1

25 Mass spectrometry: 518(MH<sup>+</sup>)

M 1702.00

Example 2:*General synthesis scheme:*

5

a) 3-H<sub>2</sub>N(C=NH)NHC<sub>6</sub>H<sub>4</sub>COOH (2a), iBuOCOCl, N-methylmorpholine; b) LiOH.*3-((Aminoiminoethyl)amino)benzoic acid hydrochloride (2a)*

10      49.4 g of 3-aminobenzoic acid were added to a solution of 108.7 g of 3,5-dimethyl-pyrazolyl-1-carboxamidine nitrate and 54.7 g of diisopropylamine in 360 ml of dioxane and 180 ml of water. The reaction solution was heated under reflux for 18 h. After cooling, it was filtered, and the crystallize was washed with dioxane/water (2:1) and dried in vacuo. The product was dissolved in water and treated with hydrochloric acid, and the hydrochloride salt was obtained after filtration as a solid product (yield: 29.7 g).

15

Melting point: 261°C.

20

'H-NMR (400 MHz, D<sub>4</sub>-MeOH): 7.51 (d, 1 H), 7.59 (t, 1 H), 7.91 (s, 1 H), 8.00 (d, 1 H).

M 17-02-00

*Ethyl 3-benzenesulphonylamino-3-[3-(3-guanidino-benzoylamino)-phenyl]-propionate  
(2b)*

0.16 ml of N-methylmorpholine and isobutyl chloroformate were added to a solution  
5 of 310 mg of (2a) in 5 ml of DMF. The solution was stirred at 0°C for 5 minutes,  
then a solution of 500 mg of (1d) in 5 ml of DMF was added at 0°C. The reaction  
mixture was warmed to RT overnight and then concentrated. A viscous oil (yield:  
502 mg) was obtained by chromatographic purification (dichloromethane/methanol =  
3:1).

10

Mass spectrometry: 510(MH<sup>+</sup>)

*3-Benzenesulphonylamino-3-[3-(3-guanidino-benzoylamino)-phenyl]-propionic acid,  
trifluoroacetic acid salt (2):*


15

64 mg of lithium hydroxide monohydrate were added to a solution of 204 mg of (2b)  
in 8 ml of water. The reaction mixture was stirred at room temperature for 48 h. The  
solution was then acidified to pH = 2 using trifluoroacetic acid and concentrated. The  
crude product was purified by RP chromatography (RP18 water/acetonitrile). A  
white solid was obtained (yield: 11 mg).

20

Mass spectrometry: 482(MH<sup>+</sup>)

M 17:02:00

**Example 3:***General synthesis scheme:*

5

- a) RCOCl, iPr<sub>2</sub>EtN; b) SnCl<sub>2</sub>, ethanol; c) 3-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl; d) SnCl<sub>2</sub>, ethanol; e) HgCl<sub>2</sub>, 1,3-bis(tert-butyloxycarbonyl)-2-methyl-2-thiopseudourea; f) TFA, dichloromethane, g) LiOH.

10      *Ethyl 3-(2,4,6-trimethylphenylacetylamo)-3-(3-nitrophenyl)-propionate (3a):*

3.57 g of mesitylacetyl chloride and 5.27 g of diisopropylethylamine were added at 0°C to a solution of 5.0 g of (1b) in 50 ml of dioxane. The reaction mixture was stirred at 0°C for 1 h, and was then allowed to warm to room temperature. The

M 17.02.00

solution was added to water and acidified with 1 N HCl, extracted with dichloromethane, dried over MgSO<sub>4</sub> and concentrated. Chromatographic purification on silica gel (dichloromethane/methanol = 20:1) afforded a white solid (yield: 6.0 g).

5       <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.09 (t, 3 H), 2.28 (s, 6 H), 2.30 (s, 3 H), 2.76 (m, 2 H), 3.65 (m, 2 H), 3.97 (m, 2 H), 5.48 (m, 1 H), 6.55 (d, 1 H), 6.97 (s, 2 H), 7.49 (m, 2 H), 7.95 (m, 1 H), 8.10 (d, 1 H).

Ethyl 3-(3-aminophenyl)-3-(2,4,6-trimethylphenylacetylamino)-propionate (3b):

10      12.5 of tin-(II) chloride were added to a solution of 6.0 g of (3a) in 180 ml of ethanol, and it was heated to reflux for 2 h. The reaction mixture was hydrolysed on ice after cooling and neutralized with NaHCO<sub>3</sub> solution (5%), then filtered through a little silica gel and washed with dichloromethane. The organic phase was dried over MgSO<sub>4</sub> and concentrated. 1.5 g of a white solid were obtained.

15      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.11 (t, 3 H), 2.25 (s, 6 H), 2.29 (s, 3 H), 2.69 (m, 2 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.33 (m, 1 H), 6.21 (d, 1 H), 6.42 (s, 1 H), 6.46 (d, 1 H), 6.53 (d, 1 H), 6.92 (s, 2 H), 7.04 (t, 1 H).

20      Ethyl 3-(3-nitrobenzenesulphonylamino)-phenyl-3-(2,4,6-trimethylphenylacetyl-amino)-propionate (3c):

25      3-Nitrobenzenesulphonyl chloride was added at 0°C to a solution of 1.5 g of (3b) in 12 ml of pyridine. After a reaction time of 2.5 h, the mixture was concentrated, treated with 1 N HCl and extracted with dichloromethane. After drying over MgSO<sub>4</sub>, the solvent was removed and 2.02 g of a solid were obtained.

30      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.07 (t, 3 H), 2.23 (s, 6 H), 2.30 (s, 3 H), 2.63 (m, 2 H), 3.63 (m, 2 H), 3.94 (m, 2 H), 5.27 (m, 1 H), 6.43 (d, 1 H), 6.87-6.95 (m, 5 H), 7.14-7.19 (m, 2 H), 7.62 (t, 1 H), 7.98 (d, 1 H), 8.37 (d, 1 H), 8.59 (s, 1 H).

H 17:02:00

- 65 -

*Ethyl 3-(3-[3-aminobenzenesulphonylamino]-phenyl)-3-(2,4,6-trimethylphenylacetyl-amino)-propionate (3d):*

5      3.8 g of tin(II) chloride were added to a solution of 2.0 g of (3c) in 30 ml of ethanol, and the reaction mixture was heated under reflux for 2 h. After cooling the solution, it was hydrolysed by pouring onto ice and neutralized with NaHCO<sub>3</sub> solution (5%). The mixture was filtered through a little silica gel, washed with dichloromethane, dried over MgSO<sub>4</sub> and concentrated. A yellowish crystalline product was obtained  
10     (yield: 1.4 g).

15     <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.09 (t, 3 H), 2.25 (s, 6 H), 2.29 (s, 3 H), 2.68 (m, 2 H), 3.63 (s, 2 H), 3.97 (m, 4 H), 5.30 (m, 1 H), 6.44 (d, 1 H), 6.48 (s, 1 H), 6.73 (d, 1 H), 6.78 (d, 1 H), 6.88 (m, 2 H), 6.93 (s, 2 H), 7.07-7.19 (m, 4 H).

20     *Ethyl 3-(2,4,6-trimethylphenylacetylamino)-3-(3-[3-N,N'-bis(t-butoxycarbonyl)-guanidino-benzenesulphonylamino]-phenyl)-propionate (3e):*

25     0.12 ml of triethylamine, 195 mg of 1,3-bis(t-butoxycarbonyl)-2-methyl-2-thio-pseudourea and 132 mg of mercuric chloride were added at 0°C to a solution of 250 mg of (3d) in 10 ml of DMF. The reaction mixture was stirred at 0°C for 30 min and at room temperature for 2.5 h. 15 ml of ethyl acetate were added, and it was stirred for 30 min before the precipitate was removed by filtration. The solution was concentrated and reused without purification.

30     Mass spectrometry: 766(MH<sup>+</sup>)

*Ethyl 3-(3-[3-guanidinobenzenesulphonylamino]-phenyl)-3-(2,4,6-trimethylphenyl-acetylamino)-propionate (3f):*

35     3 ml of trifluoroacetic acid were added to a solution of 266 mg of (3e) in 3 ml of

M 17-02-00

methylene chloride. The reaction mixture was stirred at room temperature for 4 h and concentrated. After chromatographic purification (methylene chloride/methanol = 5:1), a viscous oil was obtained (yield: 228 mg).

5 Mass spectrometry: 566(MH<sup>+</sup>)

*3-(3-[3-Guanidinobenzenesulphonylamino]-phenyl)-3-(2,4,6-trimethylphenylacetylamo)-propionic acid, trifluoroacetic acid salt (3):*

10 64 mg of lithium hydroxide monohydrate were added to a solution of 228 mg of (3f) in 30 ml of water and 30 ml of tetrahydrofuran. The reaction mixture was stirred at room temperature for 24 h. The crude product was dried in vacuo and purified by chromatography (acetonitrile/water = 7:1). 0.1 ml of trifluoroacetic acid was added and the mixture was concentrated. A white solid was obtained (yield: 100 mg).

15 Mass spectrometry: 538(MH<sup>+</sup>)

<sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 2.18 (s, 6 H), 2.23 (s, 3 H), 2.73 (m, 2 H), 3.60 (m, 2 H), 5.18 (m, 1 H), 6.84 (s, 2 H), 6.97 (d, 1 H), 7.04 (d, 1 H), 7.10 (s, 1 H), 7.20 (t, 1 H), 7.39 (d, 1 H), 7.51 (m, 2 H), 7.68 (d, 1 H).

20  
Example 4:

*Ethyl 3-benzoylamino-3-(3-nitrophenyl)-propionate (4a):*

25 Corresponding to Example 3a, 5.0 g of (1b) were acetylated by addition of benzoyl chloride. A white solid was obtained (yield: 3.3 g).

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.20 (t, 3 H), 3.02 (m, 2 H), 4.13 (q, 2 H), 5.71 (m, 1 H), 7.31-8.68 (m, 10 H).

M 17.02.00

*Ethyl 3-(3-aminophenyl)3-benzoylamino-propionate (4b):*

Corresponding to Example 3b, 3 g of (4a) were reduced using tin-(II) dichloride. A white solid was obtained (yield: 2.6 g).

5

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.19 (t, 3 H), 2.91 (dd, 1 H), 3.00 (dd, 1 H), 4.11 (q, 2 H), 5.54 (m, 1 H), 6.58 (d, 1 H), 6.68 (s, 1 H), 6.73 (s, 1 H), 7.12 (t, 1 H), 7.41-7.52 (m, 4 H), 7.84 (d, 2 H).

10

*Ethyl 3-benzoylamino-3-(3-(3-nitrobenzenesulphonylamino)-phenyl)-propionate (4c):*

Corresponding to Example 3c, 2.60 g of (4b) were reacted with 3-nitrophenylsulphonyl chloride. A solid was obtained (yield: 1.76 g).

15

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.18 (t, 3 H), 2.90 (m, 2 H), 4.09 (q, 2 H), 5.49 (m, 1 H), 7.00 (d, 1 H), 7.05 (s, 1 H), 7.11 (s, 1 H), 7.15 (d, 1 H), 7.23 (d, 1 H), 7.45-7.57 (m, 4 H), 7.70 (d, 1 H), 7.80 (d, 2 H), 7.95 (d, 1 H), 8.27 (d, 1 H), 8.58 (s, 1 H).

20

*Ethyl 3-(3-(3-aminobenzenesulphonylamino)-phenyl)-3-benzoylamino-propionate (4d):*

Corresponding to Example 3d, 1.76 g of (4c) were treated with tin-(II) chloride. A yellowish solid was obtained (yield: 779 mg).

25

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.20 (t, 3 H), 2.93 (m, 2 H), 3.98 (s, 2 H), 4.12 (q, 2 H), 5.52 (m, 1 H), 6.48 (s, 1 H), 6.67 (d, 1 H), 6.84 (d, 1 H), 6.90 (s, 1 H), 7.08-7.14 (m, 3 H), 7.20 (t, 1 H), 7.28 (m, 1 H), 7.45-7.56 (m, 3 H), 7.65 (d, 1 H), 7.84 (d, 2 H).

M 17.02.00

*Ethyl 3-benzoylamino-3-(3-[3-N,N'-bis(tert-butoxycarbonyl)guanidino-benzene-sulphonylamino]-phenyl)-propionate (4e):*

Corresponding to Example 3e, 1.76 g of (4d) were treated with mercuric chloride and  
5 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. 864 mg of the desired product were obtained.

Mass spectrometry: 710(MH<sup>+</sup>)

10 *Ethyl 3-benzoylamino-3-(3-(3-guanidinobenzenesulphonylamino)-phenyl)-propionate (4f):*

15 6 ml of trifluoroacetic acid were added to a solution of 521 mg of (4e) in 6 ml of dichloromethane. The mixture was stirred at room temperature for 4 h, concentrated and purified by chromatography (dichloromethane/methanol = 5:1). An oil was obtained (yield: 299 mg).

Mass spectrometry: 510(MH<sup>+</sup>)

20 *3-Benzoylamino-3-[3-(3-guanidino-benzenesulphonylamino)-phenyl]-propionic acid (4):*

25 94 mg of lithium hydroxide monohydrate were added to a solution of 298.5 mg of (4f) in 30 ml of water and 30 ml of THF. The reaction mixture was stirred at room temperature for 20 h and then concentrated. Chromatographic purification on silica gel (acetonitrile/water = 7:1) afforded a white solid (yield: 155 mg).

Mass spectrometry: 482(MH<sup>+</sup>)

<sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 2.81 (m, 2 H), 5.38 (m, 1 H), 6.91 (m, 1 H), 7.18 (m, 2 H), 7.34 (s, 1 H), 7.61 (s, 1 H), 7.45-7.58 (m, 5 H), 7.72 (d, 1 H), 7.86 (d, 2 H).

Example 5:

*Ethyl 3-(2,4-dichlorophenylacetylamino)-3-(3-nitrophenyl)-propionate (5a):*

5 Corresponding to Example 3a, 5.0 g of (1b) were acetylated by addition of 2,4-dichlorophenylacetyl chloride. A white solid was obtained (yield: 3.1 g).

10 <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.15 (t, 3 H), 2.87 (m, 2 H), 3.73 (s, 2 H), 4.05 (q, 2 H), 5.47 (m, 1 H), 6.99 (d, 1 H), 7.18 (d, 1 H), 7.29 (m, 1 H), 7.47 (s, 1 H), 7.50 (d, 1 H), 7.59 (d, 1 H), 8.11 (m, 2 H).

*Ethyl 3-(3-aminophenyl)-3-(2,4-dichlorophenylacetylamino)-propionate (5b):*

15 Corresponding to Example 3b, 3.1 g of (5a) were reduced using tin-(II) dichloride. A white solid was obtained (yield: 0.9 g).

20 <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.15 (t, 3 H), 2.75 (dd, 1 H), 2.84 (dd, 1 H), 3.64 (s, 2 H), 4.03 (q, 2 H), 5.31 (m, 1 H), 6.55 (m, 4 H), 7.08 (t, 1 H), 7.27 (m, 2 H), 7.43 (s, 1 H).

25 *Ethyl 3-(2,4-dichlorophenylacetylamino)-3-[3-nitrophenylsulphonylamino]-phenyl)-propionate (5c):*

Corresponding to Example 3c, 900 mg of (5b) were reacted with 3-nitrophenyl-sulphonyl chloride. A solid was obtained (yield: 1.18 g).

30 <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.12 (t, 3 H), 2.75 (m, 2 H), 3.70 (s, 2 H), 4.01 (m, 2 H), 5.28 (m, 1 H), 6.85 (d, 1 H), 6.91 (d, 1 H), 7.00 (m, 2 H), 7.18 (m, 2 H), 7.28 (m, 2 H), 7.62 (t, 1 H), 7.99 (d, 1 H), 8.37 (d, 1 H), 8.58 (s, 1 H).

M 17-02-00

- 70 -

*Ethyl 3-(3-[3-aminophenylsulphonylamino]-phenyl)-3-(2,4-dichlorophenylacetyl-amino)-propionate (5d):*

Corresponding to Example 3d, 1.18 g of (5c) were treated with tin-(II) chloride.  
5 820 mg of a yellowish solid were obtained.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.14 (t, 3 H), 2.79 (m, 2 H), 3.99 (s, 2 H), 4.03 (q, 2 H),  
5.30 (m, 1 H), 6.41 (s, 1 H), 6.73-6.83 (m, 3 H), 6.87 (s, 1 H), 6.98 (d, 1 H), 7.11-  
7.33 (m, 6 H), 7.43 (d, 1 H).

10

*Ethyl 3-(2,4-dichlorophenylacetylamino)-3-(3-[3-N,N'-bis(t-butoxycarbonyl)-guanidino-benzenesulphonylamino]-phenyl)-propionate (5e):*

Corresponding to Example 3e, 300 mg of (5d) were treated with mercuric chloride  
15 and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. 611 mg of the desired product were obtained.

Mass spectrometry: 792(MH<sup>+</sup>)

20

*Ethyl 3-(2,4-dichlorophenylacetylamino)-3-(3-guanidino-benzenesulphonyl-amino)-phenyl)-propionate (5f):*

Corresponding to Example 4f, 432 mg of (5e) were treated with trifluoroacetic acid.  
An oil was obtained (292 mg).

25

Mass spectrometry: 592(MH<sup>+</sup>)

*3-(2,4-Dichlorophenyl)-acetyl-amino)-3-[3-(3-guanidino-benzenesulphonylamino)-phenyl]-propionic acid (5):*

30

Corresponding to Example 4, 292 mg of (5f) were hydrolysed using lithium

hydroxide. A white solid was obtained (106 mg).

Mass spectrometry: 564(MH<sup>+</sup>)

- 5      <sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 2.69 (m, 2 H), 3.73 (s, 2 H), 5.18 (m, 1 H), 6.78 (d, 1 H), 7.05 (d, 1 H), 7.12 (t, 1 H), 7.27 (d, 1 H), 7.33 (m, 2 H), 7.40 (d, 1 H), 7.46 (m, 2 H), 7.54 (t, 1 H), 7.71 (d, 1 H).

**Example 6:**

10

Ethyl 3-(3-nitrophenyl)-3-phenylpropionylamino-propionate (*6a*):

15

Corresponding to Example 3a, 5.0 g of (1b) were acetylated with addition of 3-phenylpropionyl chloride. A white solid was obtained (yield: 6.7 g).

20

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.16 (t, 3 H), 2.59 (t, 2 H), 2.75 (dd, 1 H), 2.85 (dd, 1 H), 4.05 (q, 2 H), 5.45 (m, 2 H), 6.75 (d, 1 H), 7.20 (m, 3 H), 7.25 (m, 2 H), 7.45 (d, 2 H), 8.06 (s, 1 H), 8.10 (m, 1 H).

25

Ethyl 3-(3-aminophenyl)-3-phenylpropionylamino-propionate (*6b*):

20

Corresponding to Example 3b, 3.0 g of (*6a*) were reduced using tin-(II) dichloride. A white solid was obtained (yield: 1.2 g).

25

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.17 (t, 3 H), 2.51 (t, 2 H), 2.68 (dd, 1 H), 2.84 (dd, 1 H), 2.98 (t, 2 H), 3.62 (s, 2 H), 4.04 (q, 2 H), 5.30 (m, 1 H), 6.39 (d, 1 H), 6.45 (s, 1 H), 6.55 (d, 1 H), 7.07 (t, 1 H), 7.20 (m, 3 H), 7.29 (m, 2 H).

M 17.02.00

- 72 -

*Ethyl 3-[3-nitrophenylsulphonylamino]-phenyl)-3-phenylpropionylamino-propionate (6c):*

Corresponding to Example 3c, 1.2 g of (6b) were reacted with 3-nitrophenylsulphonyl chloride. A solid was obtained (yield: 1.54 g).

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.12 (t, 3 H), 2.57 (m, 2 H), 2.65 (dd, 1 H), 2.75 (dd, 1 H), 2.98 (m, 2 H), 4.00 (m, 2 H), 5.26 (m, 1 H), 6.70 (d, 1 H), 6.76 (s, 1 H), 6.88 (d, 1 H), 6.97 (d, 2 H), 7.14 (t, 1 H), 7.21 (m, 2 H), 7.23-7.32 (m, 3 H), 7.45 (s, 1 H), 10 7.61 (t, 1 H), 8.34 (d, 1 H), 8.59 (s, 1 H).

*Ethyl 3-[3-aminophenylsulphonylamino]-phenyl)-3-phenylpropionylamino-propionate (6d):*

15 Corresponding to Example 3d, 1.53 g of (6c) were treated with tin-(II) chloride. A yellowish solid was obtained (yield: 1.1 g).

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.16 (t, 3 H), 2.57 (t, 2 H), 2.68 (dd, 1 H), 2.71 (dd, 2 H), 2.98 (t, 2 H), 4.02 (s, 2 H), 4.04 (q, 2 H), 5.30 (m, 1 H), 6.33 (s 1 H), 6.61 (d, 1 H), 6.73 (d, 1 H), 6.83 (d, 1 H), 6.90 (m, 2 H), 6.97 (s, 1 H), 7.08-7.29 (m, 8 H). 20

*Ethyl 3-[3-N,N'-bis(t-butoxycarbonyl)guanidino-benzenesulphonylamino]-phenyl)-3-phenylpropionylamino-propionate (6e):*

25 Corresponding to Example 3e, 500 mg of (6d) were treated with mercuric chloride and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. 1.16 g of the desired product were obtained.

Mass spectrometry: 738(MH<sup>+</sup>)

*Ethyl 3-(3-[3-guanidino-benzenesulphonylamino]-phenyl)-3-phenylpropionylamino-propionate (6f):*

Corresponding to Example 4f, 1.16 g of (6e) were treated with trifluoroacetic acid.  
5 An oil was obtained (yield: 410 mg).

Mass spectrometry: 538(MH<sup>+</sup>)

10 *3-(3-[3-Guanidino-benzenesulphonylamino]-phenyl)-3-phenylpropionylamino-propionic acid (6):*

Corresponding to Example 4, 410 mg of (6f) were hydrolysed using lithium hydroxide. A white solid was obtained (yield: 221 mg).

15 Mass spectrometry: 510(MH<sup>+</sup>)  
<sup>1</sup>H-NMR (400 MHz, D<sub>6</sub>-MeOH): 2.49 (t, 2 H), 2.61 (m, 2 H), 2.89 (t, 2 H), 5.15 (dd, 1 H), 6.83 (d, 1 H), 6.98 (d, 1 H), 7.10 (t, 1 H), 7.15-7.24 (m, 5 H), 7.28 (s, 1 H), 7.37 (s, 1 H), 7.47 (d, 1 H), 7.55 (t, 1 H), 7.72 (d, 1 H).

20 **Example 7:**

*Ethyl 3-(3-nitrophenyl)-3-(2-phenylbutyryl-amino)-propionate (7a):*

Corresponding to Example 3a, 5.0 g of (1b) were acetylated with addition of  
25 2-phenylbutyryl chloride. A white solid was obtained (yield: 6.3 g).

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.89 (t, 3 H), 1.11 (m, 3 H), 1.82 (m, 1 H), 2.18 (m, 1 H), 2.80 (m, 2 H), 3.33 (t, 1 H), 3.99 and 4.02 (q, 2 H), 5.43 (m, 1 H), 6.78 (m, 1 H), 7.26-8.13 (m, 9 H) (mixture of diastereomers).

11/17/02 00

*Ethyl 3-(3-aminophenyl)-3-(2-phenylbutyrylamino)-propionate (7b):*

Corresponding to Example 3b, 6.3 g of (7a) were reduced using tin-(II) dichloride. A white solid was obtained (yield: 3.9 g).

5

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.88 (m, 3 H), 1.09 and 1.15 (t, 3 H), 1.80 (m, 1 H), 2.19 (m, 1 H), 2.61-2.85 (m, 2 H), 3.27 (m, 1 H), 3.95 and 4.03 (q, 2 H), 5.28 (m, 1 H), 6.41-6.59 (m, 3 H), 6.97 and 7.07 (t, 1 H), 7.25-7.37 (m, 5 H) (mixture of diastereomers).

10

*Ethyl 3-[3-nitrophenylsulphonylamino]-phenyl)-3-(2-phenylbutyrylamino)-propionate (7c):*

15

Corresponding to Example 3c, 3.9 g of (7b) were reacted with 3-nitrophenylsulphonyl chloride. A solid was obtained (yield: 5.0 g).

20

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.86 and 0.89 (t, 3 H), 1.06 and 1.10 (t, 3 H), 1.82 (m, 1 H), 2.16 (m, 1 H), 2.66 and 2.73 (m, 2 H), 3.33 and 3.34 (t, 1 H), 3.93 (m, 2 H), 5.24 (m, 1 H), 6.43-8.60 (m, 15 H) (mixture of diastereomers).

25

*Ethyl 3-[3-aminophenylsulphonylamino]-phenyl)-3-(2-phenylbutyrylamino)-propionate (7d):*

25

Corresponding to Example 3d, 5 g of (7c) were treated with tin-(II) chloride. A yellowish solid was obtained (yield: 1.8 g).

Mass spectrometry: 510(MH<sup>+</sup>)

M 17-02-00

- 75 -

*Ethyl 3-[3-{3-N,N'-bis(t-butoxycarbonyl)guanidino-benzenesulphonylamino}-phenyl]-3-(2-phenylbutyrylamino)-propionate (7e):*

Corresponding to Example 3e, 700 mg of (7d) were treated with mercuric chloride  
5 and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. 1.45 g of the desired  
product were obtained.

Mass spectrometry: 752(MH<sup>+</sup>)

10      *Ethyl 3-[3-guanidino-benzenesulphonylamino]-phenyl]-3-(2-phenylbutyrylamino)-propionate (7f):*

Corresponding to Example 4f, 1.45 g of (7e) were treated with trifluoroacetic acid.  
An oil was obtained (yield: 630 mg).


15      Mass spectrometry: 552(MH<sup>+</sup>)

*3-(3-[3-Guanidino-benzenesulphonylamino]-phenyl)-3-(2-phenylbutyrylamino)-propionic acid (7):*

20      Corresponding to Example 4, 630 mg of (7f) were hydrolysed using lithium  
hydroxide. A white solid was obtained (yield: 320 mg).

Mass spectrometry: 524(MH<sup>+</sup>)

<sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 0.82 and 0.91 (t, 3 H), 1.70-2.15 (m, 2 H), 2.67 (m,  
25      2 H), 3.42 (t, 1 H), 5.15 (m, 1 H), 6.75-7.73 (m, 13 H) (mixture of diastereomers).

Example 8:*General synthesis scheme:*

5

- a) 2-propanol, reflux; b) HCl, ethanol; c) PhSO<sub>2</sub>Cl, Et<sub>3</sub>N; d) BBr<sub>3</sub>; e) NaH, 3-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Br; f) SnCl<sub>2</sub>, ethanol; g) HgCl<sub>2</sub>, 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea; h) TFA, dichloromethane, i) LiOH.

M 17.02.00

- 77 -

*3-Amino-3-(3-methoxyphenyl)-propionic acid (8a):*

Corresponding to Example 1a, 200 g of 3-methoxybenzaldehyde were reacted with ammonium acetate and malonic acid. A white solid was obtained (yield: 135.5 g).

5

<sup>1</sup>H-NMR (400 MHz, D<sub>3</sub>-trifluoroacetic acid): 3.31 (dd, 1 H), 3.54 (dd, 1 H), 4.03 (s, 3 H), 5.00 (m, 1 H), 7.19 (m, 3 H), 7.52 (t, 1 H).

10

*Ethyl 3-Amino-3-(3-methoxyphenyl)-propionate hydrochloride (8b):*  
Corresponding to Example 1b, 60 g of (8a) were treated with hydrochloric acid in ethanol. A white, crystalline product was obtained (yield: 75 g).

15

<sup>1</sup>H-NMR (400 MHz, D<sub>4</sub>-MeOH): 1.17 (t, 3 H), 3.01 (dd, 1 H), 3.14 (dd, 1 H), 3.82 (s, 3 H), 4.14 (m, 2 H), 4.70 (m, 1 H), 6.98 (d, 1 H), 7.06 (m, 2 H), 7.37 (t, 1 H).

20

*Ethyl 3-benzenesulphonylamino-3-(3-methoxyphenyl)-propionate (8c):*  
Corresponding to Example 1c, 10 g of (8b) were treated with phenylsulphonyl chloride and triethylamine. A yellowish solid was obtained (yield: 13.2 g).

25

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.15 (t, 3 H), 2.78 (m, 2 H), 3.68 (s, 3 H), 4.02 (q, 2 H), 4.75 (q, 1 H), 5.75 (d, 1 H), 6.60 (s, 1 H), 6.69 (m, 2 H), 7.08 (t, 1 H), 7.38 (m, 2 H), 7.47 (t, 1 H), 7.71 (d, 2 H).

30

*Methyl 3-benzenesulphonylamino-3-(3-hydroxyphenyl)-propionate (8d):*

35

A solution of BBr<sub>3</sub> in dichloromethane (1 M) was added at -78°C to a solution of 2.0 g of (8c) in 50 ml of dichloromethane. After stirring at room temperature for 3 hours, the solution was cooled to -78°C and 100 ml of methanol were then added. The mixture was stirred at room temperature overnight and then concentrated.

M 17.02.00  
- 78 -

Chromatographic purification (dichloromethane/methanol = 40 : 1) afforded a white solid (yield: 1.74 g).

5       <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 2.78 (m, 2 H), 3.57 (s, 3 H), 4.71 (m, 1 H), 5.11 (s, 1 H), 5.78 (d, 1 H), 6.60 (s, 1 H), 6.65 (m, 2 H), 7.06 (t, 1 H), 7.40 (m, 2 H), 7.50 (m, 1 H), 7.74 (d, 2 H).

Methyl 3-benzenesulphonylamino-[3-(3-nitrobenzyloxy)-phenyl]-propionate (8e):

10      1.5 g of (8d) in 30 ml of THF were added to a suspension of sodium hydride (0.2 g, 60% in paraffin oil) in 10 ml of THF. The reaction mixture was stirred at room temperature for 20 h. After addition of 75 ml of a saturated NH<sub>4</sub>Cl solution, the mixture was extracted using ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, concentrated and purified by chromatography on silica gel (cyclohexane/ethyl acetate = 2 : 1). 459 mg of the corresponding benzyl ether were obtained.

15      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 2.79 (m, 2 H), 3.57 (s, 3 H), 4.75 (m, 1 H), 5.03 (s, 2 H), 5.78 (d, 1 H), 6.78 (m, 3 H), 7.16 (t, 1 H), 7.41 (m, 2 H), 7.51 (m, 1 H), 7.58 (t, 1 H), 7.75 (m, 3 H), 8.21 (d, 1 H), 8.29 (s, 1 H).

Methyl [3-(3-aminobenzyloxy)-phenyl]-3-benzenesulphonylamino-propionate (8f):

20      Corresponding to Example 3d, 442 mg of (8e) were treated with tin-(II) chloride. A yellowish solid was obtained (yield: 387 mg).

25      <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 2.79 (m, 2 H), 3.56 (s, 3 H), 3.72 (br.s, 2 H), 4.73 (m, 1 H), 4.83 (s, 2 H), 5.69 (d, 1 H), 6.67 (m, 3 H), 6.74 (m, 3 H), 7.08 (t, 1 H), 7.17 (t, 1 H), 7.38 (m, 2 H), 7.48 (m, 1 H), 7.71 (d, 2 H).

*Methyl 3-benzenesulphonylamino-3-(3-[3-N,N'-bis(tert-butoxycarbonyl)guanidino-benzyl-oxy]-phenyl)-propionate (8g):*

Corresponding to Example 3e, 382 mg of (8f) were treated with mercuric chloride  
5 and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. 563 mg of the desired product were obtained.

Mass spectrometry: 683(MH<sup>+</sup>)

*Methyl 3-benzenesulphonylamino-3-(3-[3-guanidino-benzyl oxy]-phenyl)-propionate (8h):*

Corresponding to Example 4f, 536 mg of (8g) were treated with trifluoroacetic acid. An oil was obtained (yield: 471 mg).

15 Mass spectrometry: 483(MH<sup>+</sup>)


*3-Benzenesulphonylamino-3-[3-(3-guanidino-benzyl oxy)-phenyl]-propionic acid (8):*

Corresponding to Example 4g, 471 mg of (8h) were hydrolysed using lithium hydroxide. A white solid was obtained (yield: 253 mg).

<sup>1</sup>H-NMR (400 MHz, D<sub>6</sub>-MeOH): 2.57 (m, 2 H), 4.66 (m, 1 H), 5.05 (s, 2 H), 6.67 (d, 1 H), 6.76 (d, 1 H), 6.84 (s, 1 H), 7.00 (t, 1 H), 7.19 (d, 1 H), 7.28 (s, 1 H), 7.35-7.49 (m, 5 H), 7.67 (d, 2 H).

**Example 9**

General synthesis scheme:



a) thiophosgene; b) ethanol, reflux; c) 1,2-diaminoethane, toluene, reflux; d) LiOH.

*Ethyl 3-benzenesulphonylamino-3-(3-isothiocyanatophenylsulphonylamino)-phenyl)-propionate (9a):*

10

A solution of 935 mg of NaHCO<sub>3</sub> in 20 ml of water was added to a solution of 800 mg of (1f) in 20 ml of ethyl acetate. The solution was then treated with 207 mg of thiophosgene and stirred for 1 h. After the separation of the two phases, the organic phase was washed with water, dried over MgSO<sub>4</sub>, and concentrated. After chromatographic purification (dichloromethane/methanol = 40 : 1), the product (9a) was obtained (yield: 636 mg).

15

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.13 (s, 3 H), 2.62 (dd, 1 H), 2.69 (dd, 1 H), 3.99 (q, 2 H), 4.66 (m, 1 H), 5.91 (d, 1 H), 6.74 (s, 1 H), 6.90-6.97 (m, 3 H), 7.11 (t, 1 H), 7.36-7.55 (m, 5 H), 7.62 (m, 2 H), 7.72 (d, 2 H).

5

*Ethyl 3-benzenesulphonylamino-3-(3-[3-ethoxythiocarbonylaminophenylsulphonylamino]-phenyl)-propionate (9b):*

10 200 mg of the compound (9a) were heated overnight in 5 ml of ethanol. The reaction mixture was concentrated. The product was obtained in a yield of 215 mg.

15

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.13 (s, 3 H), 1.35 (m, 3 H), 2.64 (dd, 1 H), 2.75 (dd, 1 H), 4.02 (m, 2 H), 4.55 (m, 2 H), 4.64 (m, 1 H), 5.89 (d, 1 H), 6.74 (s, 1 H), 6.82 (d, 1 H), 6.90 (d, 1 H), 7.08 (t, 1 H), 7.17 (s, 1 H), 7.39-7.47 (m, 3 H), 7.48-7.65 (m, 3 H), 7.73 (d, 2 H), 8.80 (s, 1 H).

*Ethyl 3-benzenesulphonylamino-3-{3-[3-(4,5-dihydro 1H-imidazol-2-yl-amino)-phenylsulphonylamino]-phenyl})-propionate (9c):*

20

215 mg of the compound (9b) and 33 mg of 1,2-diaminoethane were heated overnight in a mixture of 5 ml of toluene and 1 ml of DMF. The reaction mixture was concentrated, and, after chromatographic purification (dichloromethane/methanol = 1 : 1), the compound (9c) was obtained in a yield of 66 mg.

25

Mass spectrometry: 572 (MH<sup>+</sup>)

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.11 (s, 3 H), 2.59 (dd, 1 H), 2.66 (dd, 1 H), 3.55 (s, 4 H), 3.95 (m, 2 H), 4.63 (m, 1 H), 6.70 (d, 1 H), 6.83 (d, 1 H), 6.90-6.97 (m, 2 H), 7.23 (d, 1 H), 7.29 (m, 2 H), 7.39-7.49 (m, 4 H), 7.54 (d, 2 H).

M 1702.00

*3-Benzenesulphonylamino-3-[3-[3-(4,5-dihydro-1H-imidazol-2-ylamino)-phenylsulphonylamino]-phenyl]-propionic acid (9):*

Corresponding to Example 4g, 66 mg of (9c) were hydrolysed using lithium hydroxide. A white solid was obtained (yield: 47 mg).

Mass spectrometry: 544 ( $\text{MH}^+$ )  
 $^1\text{H-NMR}$  (400 MHz,  $\text{D}_4\text{-MeOH}$ ): 2.52 (dd, 1 H), 2.61 (dd, 1 H), 3.71 (s, 4 H), 4.63 (dd 1 H), 6.68 (d, 1 H), 6.78-6.96 (m, 2 H), 7.17 (s, 1 H), 7.37-7.55 (m, 6 H), 7.66 (m, 3 H).

#### Biological investigations

$\alpha,\beta_3$  from human A375 cells was purified analogously to a procedure which was described by Wong et al. (Molecular Pharmacology, 50, 529-537 (1996)). 10  $\mu\text{l}$  of  $\alpha,\beta_3$  (5 ng) in TBS pH 7.6, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1% n-octyl glucopyranoside (Sigma); 10  $\mu\text{l}$  of test substance in TBS pH 7.6, 0.1% DMSO and 45  $\mu\text{l}$  of TBS pH 7.6, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$  were in each case incubated at room temperature for 1 h. 25  $\mu\text{l}$  of WGA SPA beads (Amersham, 4 mg/ml) and 10  $\mu\text{l}$  of echistatin (0.1  $\mu\text{Ci}$ , Amersham, chloramine T-labelled) were then added in each case. After 16 hours at room temperature, the samples were measured in a scintillation measuring apparatus (Wallac 1450). The test results are shown in Table 1 below.


Table 1

Example No.	$\text{IC}_{50}-\alpha,\beta_3$ (nM)
1	19
2	390
3	153
4	12.8
5	72.4
6	36.2
7	115
8	33
9	0.295

M 17.02.00

**Claims**

## 1. Compounds of the general formula (1)



wherein

- 10       $R^1$  is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- 15       $R^2$  is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an optionally substituted alkenyl residue, an optionally substituted alkinyl residue, a hydroxyl residue or an alkoxy residue or is bonded to  $R^3$  with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which  $R^2$  is bonded and can optionally contain heteroatoms;
- 20       $R^3$  is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue, an optionally substituted alkenyl residue, an optionally substituted alkinyl residue, a hydroxyl residue or an alkoxy residue or is bonded to  $R^2$  with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which  $R^3$  is bonded and can optionally contain heteroatoms;
- 25       $R^4$  is  $-SO_2R^{4''}$ ,  $-COOR^{4''}$ ,  $-COR^{4''}$ ,  $-CONR^{4''}_2$  or  $-CSNR^{4''}_2$ ;

M 17-02-00

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

- R<sup>4</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- 5 R<sup>4</sup> is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- R<sup>5</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue or a substituted or unsubstituted aryl residue;
- 10 R<sup>10</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom;
- R<sup>11</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted alkoxy residue or a halogen atom;
- L is -(CH<sub>2</sub>)<sub>m</sub>NHSO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NH(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>NHCO(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CONH(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>OCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>COO(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>OOC(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>CO(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>COCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , -NHCONH- , -(CH<sub>2</sub>)<sub>m</sub>SCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>S(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>SOCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , -(CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- or -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>- , wherein m and n are each an integer of 0 or 1 and m + n ≤ 1;
- 20 R<sup>6</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue or is bonded to one of R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>6</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;
- X is N, O or S;
- 25 R<sup>7</sup> is absent, is -H, a substituted or unsubstituted alkyl or cycloalkyl residue, -NO<sub>2</sub>, -CN, -COR<sup>7</sup>, -COOR<sup>7</sup>, or is bonded to one of R<sup>6</sup>, R<sup>8</sup> or R<sup>9</sup> with formation of an optionally substituted heterocyclic ring

M 17.02.00

system which includes X and can be saturated or unsaturated and/or can contain further heteroatoms;

R<sup>7</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue which can be saturated or unsaturated and/or can contain further heteroatoms;

5 R<sup>8</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>8</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;

10 R<sup>9</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue, a saturated or unsaturated, optionally substituted heterocyclic residue or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;

15 20 and their physiologically acceptable salts and stereoisomers.

2. Compounds according to Claim 1,

characterized in that

25 R<sup>1</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof;

R<sup>2</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue, an alkenyl residue, an alkinyl residue or a substituted derivative thereof; a hydroxyl residue or a C<sub>1-6</sub>-alkoxy residue or is bonded to R<sup>3</sup> with formation of an optionally substituted carbocyclic

30

- M 17-00-00
- or heterocyclic ring system which includes the carbon atom to which R<sup>2</sup> is bonded and can optionally contain heteroatoms;
- 5      R<sup>3</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue, an alkenyl residue, an alkynyl residue or a substituted derivative thereof; a hydroxyl residue or a C<sub>1-6</sub>-alkoxy residue or is bonded to R<sup>2</sup> with formation of an optionally substituted carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>3</sup> is bonded and can optionally contain heteroatoms;
- 10     R<sup>4</sup> is -SO<sub>2</sub>R<sup>4'</sup>, -COOR<sup>4''</sup>, -COR<sup>4'</sup>, -CONR<sup>4'</sup><sub>2</sub> or -CSNR<sup>4'</sup><sub>2</sub>;
- 15     R<sup>4'</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- 20     R<sup>4''</sup> is a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue;
- 25     R<sup>5</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof;
- 30     R<sup>10</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a C<sub>1-6</sub> alkoxy residue or a substituted derivative thereof or F, Cl, Br or I;
- R<sup>11</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, a C<sub>1-6</sub> alkoxy residue or a substituted derivative thereof or F, Cl, Br or I;
- L is -NHSO<sub>2</sub>-, -CH<sub>2</sub>NHSO<sub>2</sub>-, -NHSO<sub>2</sub>CH<sub>2</sub>-, -SO<sub>2</sub>NH-, -CH<sub>2</sub>SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCH<sub>2</sub>-, -NHCO-, -CH<sub>2</sub>NHCO-, -NHCOCH<sub>2</sub>-, -CONH-, -CH<sub>2</sub>CONH-, -CONHCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-  
          -CH<sub>2</sub>CH<sub>2</sub>O-, -COO-, -CH<sub>2</sub>COO-, -COOCH<sub>2</sub>-, -OOC-, -OOCCH<sub>2</sub>-, -CH<sub>2</sub>OOC-, -CH<sub>2</sub>CO-, -COCH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CO-, -COCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>COCH<sub>2</sub>-, -NHCONH-, -SCH<sub>2</sub>-, -CH<sub>2</sub>S-, -CH<sub>2</sub>SCH<sub>2</sub>, -SCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>S-, -SOCH<sub>2</sub>-, -CH<sub>2</sub>SO-, -CH<sub>2</sub>SOCH<sub>2</sub>-, -SOCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO-, -SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>-, -CH<sub>2</sub>SO<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-,

M 17-02-00

- 5            R<sup>6</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>6</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms;
- 10          X is O, N or S;
- 10          R<sup>7</sup> is absent, is -H, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, -NO<sub>2</sub>, -CN, -COR<sup>1</sup>, -COOR<sup>1</sup>, or is bonded to one of R<sup>6</sup>, R<sup>8</sup> or R<sup>9</sup> with formation of an optionally substituted heterocyclic ring system which includes X and can be saturated or unsaturated and/or can contain further heteroatoms;
- 15          R<sup>7</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof;
- 15          R<sup>8</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>8</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms; and
- 20          R<sup>9</sup> is hydrogen, a C<sub>1-6</sub>-alkyl residue, a C<sub>3-7</sub>-cycloalkyl residue, an aryl residue or a substituted derivative thereof or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms.

3. Compounds according to Claim 1,  
characterized in that -
- 30          R<sup>1</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclo-

pentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof;

- 5           R<sup>2</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -OH, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, benzyloxy or is bonded to R<sup>3</sup> with formation of an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>2</sup> is bonded and can optionally contain heteroatoms;
- 10          R<sup>3</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -OH, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, or is bonded to R<sup>2</sup> with formation of an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring system which includes the carbon atom to which R<sup>3</sup> is bonded and can optionally contain heteroatoms;
- 15          R<sup>4</sup> is -SO<sub>2</sub>R<sup>4'</sup> or -COR<sup>4'</sup>;
- 20          R<sup>4'</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thio-


M 17.02.00

- 89 -


- phenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methylbenzothiazol-2-yl, N-methoxycarbonylpiperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl;
- 15      R<sup>5</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl or
- 20

M 17-02-00


- 90 -




(a1)




(a2)




(a3)




(a4)




(a5)




(a6)




(a7)




(a8)




(a9)




(a10)




(a11)




(a12)




(a13)




(a14)




(a15)



(a16) (a17) (a18) (a19) (a20)



(a21) (a22) (a23) (a24)



(a25) (a26) (a27) (a28)

R<sup>10</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, fluorine, chlorine, bromine or iodine;

R<sup>11</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, fluorine, chlorine, bromine or iodine;

L is -NHSO<sub>2</sub>- , -CH<sub>2</sub>NHSO<sub>2</sub>- , -NHSO<sub>2</sub>CH<sub>2</sub>- , -SO<sub>2</sub>NH- , -CH<sub>2</sub>SO<sub>2</sub>NH- , -SO<sub>2</sub>NHCH<sub>2</sub>- , -NHCO- , -CH<sub>2</sub>NHCO- , -NHCOCH<sub>2</sub>- , -CONH- ,

M 17-02-00

- 92 -

- CH<sub>2</sub>CONH-, -CONHCH<sub>2</sub>-, -OCH<sub>2</sub>-, -CH<sub>2</sub>OCH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>O-  
or -CH<sub>2</sub>CH<sub>2</sub>O-;
- R<sup>6</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,  
pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl,  
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl,  
3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or  
a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-  
dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one  
of the residues (a1) to (a28) or is bonded to one of R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup>, if  
present, with formation of an optionally substituted heterocyclic 4- to  
6-membered ring system which includes the nitrogen atom to which  
R<sup>6</sup> is bonded and can be saturated or unsaturated and/or can contain  
further heteroatoms;
- X is N, O or S;
- R<sup>7</sup> is absent, is -H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-  
butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl,  
cyclopentyl, cyclohexyl, cycloheptyl, -NO<sub>2</sub>, -CN, -COR<sup>7</sup>, -COOR<sup>7</sup> or  
is bonded to one of R<sup>6</sup>, R<sup>8</sup> or R<sup>9</sup> with formation of an optionally  
substituted carbocyclic or heterocyclic 4- to 6-membered ring system  
which includes X and can be saturated or unsaturated and/or can  
contain further heteroatoms;
- R<sup>7</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,  
pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclo-  
pentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted  
derivative thereof;
- R<sup>8</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,  
pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl,  
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl,  
3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or  
a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-  
dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one

of the residues (a1) to (a28) or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>9</sup>, if present, with formation of an optionally substituted heterocyclic 4- to 6-membered ring system which includes the nitrogen atom to which R<sup>8</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms; and

R<sup>9</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 3,3,5-trimethylcyclohexyl, 5-methyl-2-hexyl, phenyl, benzyl, tolyl or a substituted derivative thereof, C<sub>1-4</sub>-alkylamino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-dialkylamino-C<sub>1-4</sub>-alkyl, amino-C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkyloxy-C<sub>1-4</sub>-alkyl, one of the residues (a1) to (a28) or is bonded to one of R<sup>6</sup>, R<sup>7</sup> or R<sup>8</sup>, if present, with formation of an optionally substituted heterocyclic 4- to 6-membered ring system which includes the nitrogen atom to which R<sup>9</sup> is bonded and can be saturated or unsaturated and/or can contain further heteroatoms.

4. Compounds according to Claim 3,

characterized in that

R<sup>4</sup> is -SO<sub>2</sub>R<sup>4</sup>;

R<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted derivative thereof, -C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-

- camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl,  
4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methyl-  
phenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-  
methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-  
naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methyl-  
phenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimeth-  
oxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-  
alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-meth-  
oxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-meth-  
yl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-  
2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl, benzyloxy,  
5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-  
dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-  
triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quin-  
olinyl;
- L is  $\text{-NHSO}_2-$ ,  $\text{-CH}_2\text{NHSO}_2-$ ,  $\text{-NHSO}_2\text{CH}_2-$ ;  
X is N;
- and the other residues are as defined in Claim 3.
- 20 5. Compounds according to Claim 3,  
characterized in that  
R<sup>4</sup> is  $\text{-COR}^4$ ;  
R<sup>4</sup> is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,  
pentyl, isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclo-  
pentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted  
derivative thereof,  $\text{-C}_6\text{H}_2(\text{CH}_3)_3$ ,  $\text{-C}_6(\text{CH}_3)_5$ ,  $\text{-CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-  
chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl,  
2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-  
dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-di-  
chlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonyl-  
phenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-

17.02.00

bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl,  
2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-  
(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thio-  
phenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-  
methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl,  
2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-  
naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methyl-  
phenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimeth-  
oxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-  
alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-meth-  
oxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-  
methylbenzothiazol-2-yl, N-methoxycarbonylpiperidin-3-yl, thiophen-  
2-yl, isoxazol-5-yl, ethoxy, 2-chloropyridin-3-yl, pyridin-3-yl, benzyl-  
oxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl,  
2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-  
triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quini-  
olinyl;

L is  $\text{-NSO}_2-$ ,  $\text{-CH}_2\text{NSO}_2-$  or  $\text{-NSO}_2\text{CH}_2-$ ;

X is N;

and the other residues are as defined in Claim 1.

6. Compounds according to Claim 3,

characterized in that

R<sup>4</sup> is  $\text{-SO}_2\text{R}'$ ;

R<sup>4</sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl,  
isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,  
cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted  
derivative thereof,  $\text{-C}_6\text{H}_2(\text{CH}_3)_3$ ,  $\text{-C}_6(\text{CH}_3)_5$ ,  $\text{-CH}_2\text{C}_6\text{H}_2(\text{CH}_3)_3$ , 2-chloro-  
phenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-  
dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-di-  
chlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-di-

M 17-02-00

chlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbon-  
ylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl,  
3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenyl-  
methyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenyl-  
propyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenyl-  
ethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-  
methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-  
dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethyl-  
phenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl,  
2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxy-  
phenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoro-  
methylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-  
acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-  
chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-  
yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl,  
benzyloxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxy-  
methyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-  
dimethyl-1,3,4-triazaindolizin-2-yl, (S)-camphan-1-yl, (R)-camphan-  
1-yl or 8-quinolinyl;

20      L      is -NHCO-, -CH<sub>2</sub>NHCO- or -NHCOCH<sub>2</sub>-;  
X      is N;


and the other residues are as defined in Claim 3.

7. Compounds according to Claim 3,  
characterized in that
- 25      R<sup>4</sup>      is -SO<sub>2</sub>R<sup>4</sup>;  
R<sup>4</sup>      is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl,  
isopentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl,  
cyclohexyl, cycloheptyl, phenyl, benzyl, tolyl or a substituted  
30      derivative thereof, -C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, -C<sub>6</sub>(CH<sub>3</sub>)<sub>5</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(CH<sub>3</sub>)<sub>3</sub>, 2-  
chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl,

2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-di-  
 chlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-di-  
 chlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonyl-  
 phenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-  
 bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl,  
 5  
 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-  
 (+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thio-  
 phenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-  
 methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl,  
 10  
 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-  
 naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methyl-  
 phenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimeth-  
 oxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-  
 alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-meth-  
 oxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-meth-  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55  
 60  
 65  
 70  
 75  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
 465  
 470  
 475  
 480  
 485  
 490  
 495  
 500  
 505  
 510  
 515  
 520  
 525  
 530  
 535  
 540  
 545  
 550  
 555  
 560  
 565  
 570  
 575  
 580  
 585  
 590  
 595  
 600  
 605  
 610  
 615  
 620  
 625  
 630  
 635  
 640  
 645  
 650  
 655  
 660  
 665  
 670  
 675  
 680  
 685  
 690  
 695  
 700  
 705  
 710  
 715  
 720  
 725  
 730  
 735  
 740  
 745  
 750  
 755  
 760  
 765  
 770  
 775  
 780  
 785  
 790  
 795  
 800  
 805  
 810  
 815  
 820  
 825  
 830  
 835  
 840  
 845  
 850  
 855  
 860  
 865  
 870  
 875  
 880  
 885  
 890  
 895  
 900  
 905  
 910  
 915  
 920  
 925  
 930  
 935  
 940  
 945  
 950  
 955  
 960  
 965  
 970  
 975  
 980  
 985  
 990  
 995  
 1000  
 1005  
 1010  
 1015  
 1020  
 1025  
 1030  
 1035  
 1040  
 1045  
 1050  
 1055  
 1060  
 1065  
 1070  
 1075  
 1080  
 1085  
 1090  
 1095  
 1100  
 1105  
 1110  
 1115  
 1120  
 1125  
 1130  
 1135  
 1140  
 1145  
 1150  
 1155  
 1160  
 1165  
 1170  
 1175  
 1180  
 1185  
 1190  
 1195  
 1200  
 1205  
 1210  
 1215  
 1220  
 1225  
 1230  
 1235  
 1240  
 1245  
 1250  
 1255  
 1260  
 1265  
 1270  
 1275  
 1280  
 1285  
 1290  
 1295  
 1300  
 1305  
 1310  
 1315  
 1320  
 1325  
 1330  
 1335  
 1340  
 1345  
 1350  
 1355  
 1360  
 1365  
 1370  
 1375  
 1380  
 1385  
 1390  
 1395  
 1400  
 1405  
 1410  
 1415  
 1420  
 1425  
 1430  
 1435  
 1440  
 1445  
 1450  
 1455  
 1460  
 1465  
 1470  
 1475  
 1480  
 1485  
 1490  
 1495  
 1500  
 1505  
 1510  
 1515  
 1520  
 1525  
 1530  
 1535  
 1540  
 1545  
 1550  
 1555  
 1560  
 1565  
 1570  
 1575  
 1580  
 1585  
 1590  
 1595  
 1600  
 1605  
 1610  
 1615  
 1620  
 1625  
 1630  
 1635  
 1640  
 1645  
 1650  
 1655  
 1660  
 1665  
 1670  
 1675  
 1680  
 1685  
 1690  
 1695  
 1700  
 1705  
 1710  
 1715  
 1720  
 1725  
 1730  
 1735  
 1740  
 1745  
 1750  
 1755  
 1760  
 1765  
 1770  
 1775  
 1780  
 1785  
 1790  
 1795  
 1800  
 1805  
 1810  
 1815  
 1820  
 1825  
 1830  
 1835  
 1840  
 1845  
 1850  
 1855  
 1860  
 1865  
 1870  
 1875  
 1880  
 1885  
 1890  
 1895  
 1900  
 1905  
 1910  
 1915  
 1920  
 1925  
 1930  
 1935  
 1940  
 1945  
 1950  
 1955  
 1960  
 1965  
 1970  
 1975  
 1980  
 1985  
 1990  
 1995  
 2000  
 2005  
 2010  
 2015  
 2020  
 2025  
 2030  
 2035  
 2040  
 2045  
 2050  
 2055  
 2060  
 2065  
 2070  
 2075  
 2080  
 2085  
 2090  
 2095  
 2100  
 2105  
 2110  
 2115  
 2120  
 2125  
 2130  
 2135  
 2140  
 2145  
 2150  
 2155  
 2160  
 2165  
 2170  
 2175  
 2180  
 2185  
 2190  
 2195  
 2200  
 2205  
 2210  
 2215  
 2220  
 2225  
 2230  
 2235  
 2240  
 2245  
 2250  
 2255  
 2260  
 2265  
 2270  
 2275  
 2280  
 2285  
 2290  
 2295  
 2300  
 2305  
 2310  
 2315  
 2320  
 2325  
 2330  
 2335  
 2340  
 2345  
 2350  
 2355  
 2360  
 2365  
 2370  
 2375  
 2380  
 2385  
 2390  
 2395  
 2400  
 2405  
 2410  
 2415  
 2420  
 2425  
 2430  
 2435  
 2440  
 2445  
 2450  
 2455  
 2460  
 2465  
 2470  
 2475  
 2480  
 2485  
 2490  
 2495  
 2500  
 2505  
 2510  
 2515  
 2520  
 2525  
 2530  
 2535  
 2540  
 2545  
 2550  
 2555  
 2560  
 2565  
 2570  
 2575  
 2580  
 2585  
 2590  
 2595  
 2600  
 2605  
 2610  
 2615  
 2620  
 2625  
 2630  
 2635  
 2640  
 2645  
 2650  
 2655  
 2660  
 2665  
 2670  
 2675  
 2680  
 2685  
 2690  
 2695  
 2700  
 2705  
 2710  
 2715  
 2720  
 2725  
 2730  
 2735  
 2740  
 2745  
 2750  
 2755  
 2760  
 2765  
 2770  
 2775  
 2780  
 2785  
 2790  
 2795  
 2800  
 2805  
 2810  
 2815  
 2820  
 2825  
 2830  
 2835  
 2840  
 2845  
 2850  
 2855  
 2860  
 2865  
 2870  
 2875  
 2880  
 2885  
 2890  
 2895  
 2900  
 2905  
 2910  
 2915  
 2920  
 2925  
 2930  
 2935  
 2940  
 2945  
 2950  
 2955  
 2960  
 2965  
 2970  
 2975  
 2980  
 2985  
 2990  
 2995  
 3000  
 3005  
 3010  
 3015  
 3020  
 3025  
 3030  
 3035  
 3040  
 3045  
 3050  
 3055  
 3060  
 3065  
 3070  
 3075  
 3080  
 3085  
 3090  
 3095  
 3100  
 3105  
 3110  
 3115  
 3120  
 3125  
 3130  
 3135  
 3140  
 3145  
 3150  
 3155  
 3160  
 3165  
 3170  
 3175  
 3180  
 3185  
 3190  
 3195  
 3200  
 3205  
 3210  
 3215  
 3220  
 3225  
 3230  
 3235  
 3240  
 3245  
 3250  
 3255  
 3260  
 3265  
 3270  
 3275  
 3280  
 3285  
 3290  
 3295  
 3300  
 3305  
 3310  
 3315  
 3320  
 3325  
 3330  
 3335  
 3340  
 3345  
 3350  
 3355  
 3360  
 3365  
 3370  
 3375  
 3380  
 3385  
 3390  
 3395  
 3400  
 3405  
 3410  
 3415  
 3420  
 3425  
 3430  
 3435  
 3440  
 3445  
 3450  
 3455  
 3460  
 3465  
 3470  
 3475  
 3480  
 3485  
 3490  
 3495  
 3500  
 3505  
 3510  
 3515  
 3520  
 3525  
 3530  
 3535  
 3540  
 3545  
 3550  
 3555  
 3560  
 3565  
 3570  
 3575  
 3580  
 3585  
 3590  
 3595  
 3600  
 3605  
 3610  
 3615  
 3620  
 3625  
 3630  
 3635  
 3640  
 3645  
 3650  
 3655  
 3660  
 3665  
 3670  
 3675  
 3680  
 3685  
 3690  
 3695  
 3700  
 3705  
 3710  
 3715  
 3720  
 3725  
 3730  
 3735  
 3740  
 3745  
 3750  
 3755  
 3760  
 3765  
 3770  
 3775  
 3780  
 3785  
 3790  
 3795  
 3800  
 3805  
 3810  
 3815  
 3820  
 3825  
 3830  
 3835  
 3840  
 3845  
 3850  
 3855  
 3860  
 3865  
 3870  
 3875  
 3880  
 3885  
 3890  
 3895  
 3900  
 3905  
 3910  
 3915  
 3920  
 3925  
 3930  
 3935  
 3940  
 3945  
 3950  
 3955  
 3960  
 3965  
 3970  
 3975  
 3980  
 3985  
 3990  
 3995  
 4000  
 4005  
 4010  
 4015  
 4020  
 4025  
 4030  
 4035  
 4040  
 4045  
 4050  
 4055  
 4060  
 4065  
 4070  
 4075  
 4080  
 4085  
 4090  
 4095  
 4100  
 4105  
 4110  
 4115  
 4120  
 4125  
 4130  
 4135  
 4140  
 4145  
 4150  
 4155  
 4160  
 4165  
 4170  
 4175  
 4180  
 4185  
 4190  
 4195  
 4200  
 4205  
 4210  
 4215  
 4220  
 4225  
 4230  
 4235  
 4240  
 4245  
 4250  
 4255  
 4260  
 4265  
 4270  
 4275  
 4280  
 4285  
 4290  
 4295  
 4300  
 4305  
 4310  
 4315  
 4320  
 4325  
 4330  
 4335  
 4340  
 4345  
 4350  
 4355  
 4360  
 4365  
 4370  
 4375  
 4380  
 4385  
 4390  
 4395  
 4400  
 4405  
 4410  
 4415  
 4420  
 4425  
 4430  
 4435  
 4440  
 4445  
 4450  
 4455  
 4460  
 4465  
 4470  
 4475  
 4480  
 4485  
 4490  
 4495  
 4500  
 4505  
 4510  
 4515  
 4520  
 4525  
 4530  
 4535  
 4540  
 4545  
 4550  
 4555  
 4560  
 4565  
 4570  
 4575  
 4580  
 4585  
 4590  
 4595  
 4600  
 4605  
 4610  
 4615  
 4620  
 4625  
 4630  
 4635  
 4640  
 4645  
 4650  
 4655  
 4660  
 4665  
 4670  
 4675  
 4680  
 4685  
 4690  
 4695  
 4700  
 4705  
 4710  
 4715  
 4720  
 4725  
 4730  
 4735  
 4740  
 4745  
 4750  
 4755  
 4760  
 4765  
 4770  
 4775  
 4780  
 4785  
 4790  
 4795  
 4800  
 4805  
 4810  
 4815  
 4820  
 4825  
 4830  
 4835  
 4840  
 4845  
 4850  
 4855  
 4860  
 4865  
 4870  
 4875  
 4880  
 4885  
 4890  
 4895  
 4900  
 4905  
 4910  
 4915  
 4920  
 4925  
 4930  
 4935  
 4940  
 4945  
 4950  
 4955  
 4960  
 4965  
 4970  
 4975  
 4980  
 4985  
 4990  
 4995  
 5000  
 5005  
 5010  
 5015  
 5020  
 5025  
 5030  
 5035  
 5040  
 5045  
 5050  
 5055  
 5060  
 5065  
 5070  
 5075  
 5080  
 5085  
 5090  
 5095  
 5100  
 5105  
 5110  
 5115  
 5120  
 5125  
 5130  
 5135  
 5140  
 5145  
 5150  
 5155  
 5160  
 5165  
 5170  
 5175  
 5180  
 5185  
 5190  
 5195  
 5200  
 5205  
 5210  
 5215  
 5220  
 5225  
 5230  
 5235  
 5240  
 5245  
 5250  
 5255  
 5260  
 5265  
 5270  
 5275  
 5280  
 5285  
 5290  
 5295  
 5300  
 5305  
 5310  
 5315  
 5320  
 5325  
 5330  
 5335  
 5340  
 5345  
 5350  
 5355  
 5360  
 5365  
 5370  
 5375  
 5380  
 5385  
 5390  
 5395  
 5400  
 5405  
 5410  
 5415  
 5420  
 5425  
 5430  
 5435  
 5440  
 5445  
 5450  
 5455  
 5460  
 5465  
 5470  
 5475  
 5480  
 5485  
 5490  
 5495  
 5500  
 5505  
 5510  
 5515  
 5520  
 5525  
 5530  
 5535  
 5540  
 5545  
 5550  
 5555  
 5560  
 5565  
 5570  
 5575  
 5580  
 5585  
 5590  
 5595  
 5600  
 5605  
 5610  
 5615  
 5620  
 5625  
 5630  
 5635  
 5640  
 5645  
 5650  
 5655  
 5660  
 5665  
 5670  
 5675  
 5680  
 5685  
 5690  
 5695  
 5700  
 5705  
 5710  
 5715  
 5720  
 5725  
 5730  
 5735  
 5740  
 5745  
 5750  
 5755  
 5760  
 5765  
 5770  
 5775  
 5780  
 5785  
 5790  
 5795  
 5800  
 5805  
 5810  
 5815  
 5820  
 5825  
 5830  
 5835  
 5840  
 5845  
 5850  
 5855  
 5860  
 5865  
 5870  
 5875  
 5880  
 5885  
 5890  
 5895  
 5900  
 5905  
 5910  
 5915  
 5920  
 5925  
 5930  
 5935  
 5940  
 5945  
 5950  
 5955  
 5960  
 5965  
 5970  
 5975  
 5980  
 5985  
 5990  
 5995  
 6000  
 6005  
 6010  
 6015  
 6020  
 6025  
 6030  
 6035  
 6040  
 6045  
 6050  
 6055  
 6060  
 6065  
 6070  
 6075  
 6080  
 6085  
 6090  
 6095  
 6100  
 6105  
 6110  
 6115  
 6120  
 6125  
 6130  
 6135  
 6140  
 6145  
 6150  
 6155  
 6160  
 6165  
 6170  
 6175  
 6180  
 6185  
 6190  
 6195  
 6200  
 6205  
 6210  
 6215  
 6220  
 6225  
 6230  
 6235  
 6240  
 6245  
 6250  
 6255  
 6260  
 6265  
 6270  
 6275  
 6280  
 6285  
 6290  
 6295  
 6300  
 6305  
 6310  
 6315  
 6320  
 6325  
 6330  
 6335  
 6340  
 6345  
 6350  
 6355  
 6360  
 6365  
 6370  
 6375  
 6380  
 6385  
 6390  
 6395  
 6400  
 6405  
 6410  
 6415  
 6420  
 6425  
 6430  
 6435  
 6440  
 6445  
 6450  
 6455  
 6460  
 6465  
 6470  
 6475  
 6480  
 6485  
 6490  
 6495  
 6500  
 6505  
 6510  
 6515  
 6520  
 6525  
 6530  
 6535  
 6540  
 6545  
 6550  
 6555  
 6560  
 6565  
 6570  
 6575  
 6580  
 6585  
 6590  
 6595  
 6600  
 6605  
 6610  
 6615  
 6620  
 6625  
 6630  
 6635  
 6640  
 6645  
 6650  
 6655  
 6660  
 6665  
 6670  
 6675  
 6680  
 6685  
 6690  
 6695  
 6700  
 6705  
 6710  
 6715  
 6720  
 6725  
 6730  
 6735  
 6740  
 6745  
 6750  
 6755  
 6760  
 6765  
 6770  
 6775  
 6780  
 6785  
 6790  
 6795  
 6800  
 6805  
 6810  
 6815  
 6820


- 5 phenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 4-chlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 2-methoxycarbonylphenylmethyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-trifluoromethoxyphenyl, phenylmethyl, 2-acetamido-4-methyl-thiazol-5-yl, phenylethyl, 1-phenylpropyl, (S)-(+)-camphor-10-yl, (R)-(-)-camphor-10-yl, 2-phenylethenyl, 2-thiophenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-propylphenyl, 2,5-dimethylphenyl, 2-methoxy-5-methylphenyl, 2,3,5,6-tetramethylphenyl, 1-naphthyl, 2-naphthyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chloro-6-methylphenyl, 2-chloro-4-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-chloro-6-methoxyphenyl, 2-trifluoromethylphenyl, 2-alkylsulphonylphenyl, 2-arylsulphonylphenyl, 3-(N-acetyl-6-methoxy)aniline, 4-acetamidophenyl, 2,2,2-trifluoroethyl, 5-chloro-3-methyl-benzothiazol-2-yl, N-methoxycarbonyl-piperidin-3-yl, thiophen-2-yl, isoxazol-5-yl, 2-chloropyridin-3-yl, pyridin-3-yl, benzyl-oxy, 5-methylisoxazol-3-yl, 1-adamantyl, 4-chlorophenoxyethyl, 2,2-dimethylethenyl, 2-chloropyridine-5-methyl, 5,7-dimethyl-1,3,4-triazaindolin-2-yl, (S)-camphan-1-yl, (R)-camphan-1-yl or 8-quinolinyl;
- 10 L is  $-NHSO_2-$ ,  $-CH_2NHSO_2-$  or  $-NHSO_2CH_2-$ ;
- 15 X is N;
- 20 R<sup>7</sup> and R<sup>9</sup> together form an ethylene group which bonds the nitrogen atom to which R<sup>7</sup> is bonded to the nitrogen atom to which R<sup>9</sup> is bonded; and the other residues are as defined in Claim 3.

## 9. Process for the preparation of compounds of the formula (1)



comprising the steps


- a) reaction of a  $\beta$ -amino acid of the formula (2)



wherein

P is  $-(CH_2)_mNO_2$ ,  $-(CH_2)_mO-C_{1-6}$ -alkyl,  $-(CH_2)_mSO_2P'$ ,  
 $-(CH_2)_mCOP'$ ,  
 $-(CH_2)_mCH_2O-C_{1-6}$ -alkyl, wherein m in each case is an integer  
of 0 or 1;  
P' is -OH, -O-C<sub>1-6</sub>-alkyl,  
and the other residues are as defined in Claim 1

with a compound R<sup>4</sup>-A to give a compound of the formula (3);



wherein


R<sup>4</sup> is  $-SO_2R^{4\prime}$ ,  $-COOR^{4\prime\prime}$ , or  $-COR^{4\prime\prime}$ ;  
R<sup>4\prime</sup> and R<sup>4\prime\prime</sup> are as defined in Claim 1;  
A is -Cl, -Br, -I, -O-triflyl, -O-tosyl, -O-C<sub>1-6</sub>-alkyl,  
-O-CO-C<sub>1-6</sub>-alkyl, -O-CO-O-C<sub>1-6</sub>-alkyl, -OC(CH<sub>3</sub>)=CH<sub>2</sub>;

M 17-02-00

- 100 -

and the other residues are as defined above;

- b) conversion of the residue P into the residue Q, wherein
  - Q is  $-(CH_2)_mNH_2$ ,  $-(CH_2)_mOH$ ,  $-(CH_2)_mCH_2OH$ ,  $-(CH_2)_mSO_2A$ ,
  - 5  $-(CH_2)_mCOA$ ,
  - A is as defined above;
  - m is an integer of 0 or 1;
- c) reaction of the compound obtained from step b) with a compound of
  - 10 the formula (4)




wherein

S is  $ASO_2(CH_2)_n^-$ ,  $NH_2(CH_2)_n^-$ ,  $ACO(CH_2)_n^-$ ,  $HOCH_2(CH_2)_n^-$ ,  
 M( $CH_2$ )<sub>n</sub><sup>-</sup>,  $MCH_2(CH_2)_n^-$ ,  $HSCH_2(CH_2)_n^-$  or  $HS(CH_2)_n^-$ ,  
 15 wherein n is an integer of 0 or 1;

M is a residue including Mg, Li, Cd or Sn;

A is as defined above; and

C is  $-NO_2$  or




X, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> are as defined in Claim 1;

20 to give a compound of the formula (5)

M 17.02.00


- 101 -



wherein the residues are as defined in Claim 1;

- 5           d) if appropriate, conversion of C, if C is a nitro group, into an optionally cyclic urea, thiourea or guanidine unit with obtainment of the compound (1); and
- 10          e) if appropriate, removal of protective groups and/or derivatization of nitrogen atoms, which are present, at preferred times within the preparation process, and/or conversion of the compound obtained into the free acid and/or conversion of the compound obtained into one of its physiological salts by reaction with an inorganic or organic base or acid.
- 15          10. Process according to Claim 9,  
characterized in that  
the β-amino acid of the formula (2) is obtained by reaction of malonic acid with a benzaldehyde derivative of the formula (2a)

20



M 17-00-00

- 102

wherein R<sup>10</sup> and P are as defined in Claim 9, in the presence of ammonia, ammonium compounds or amines and, if appropriate, subsequent substitution in the  $\alpha$ -position to the terminal carboxyl group.

- 5        11. Process according to Claim 9,  
              characterized in that  
              it comprises the conversion of the nitro group in step d) by reduction to the  
              amino group, subsequent reaction with a carbonic acid derivative and, if  
              appropriate, removal of protective groups present and/or reaction with a  
10      compound containing at least one amino group.

12. Pharmaceutical composition, comprising at least one compound according to  
one of Claims 1 to 10.

15      13. Use of compounds according to one of Claims 1 to 10 for the production of a  
pharmaceutical composition having integrin-antagonistic action.

20      14. Use of compounds according to one of Claims 1 to 10 for the production of a  
pharmaceutical composition for the therapy and prophylaxis of cancer,  
osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis and  
ophthalmic disorders.


M 17-02-00

- 103 -

## **β-Phenylalanine derivatives as integrin antagonists**

## Abstract

The present invention relates to compounds of the general formula (1)



wherein R<sup>4</sup> is -SO<sub>2</sub>R<sup>4'</sup>, -COOR<sup>4''</sup>, -COR<sup>4'</sup>, -CONR<sup>4'</sup><sub>2</sub> or -CSNR<sup>4'</sup><sub>2</sub>; R<sup>4'</sup> is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R<sup>4''</sup> is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers. The present invention furthermore relates to a process for the preparation of the compounds of the formula (1), a pharmaceutical composition containing at least one of these compounds, and the use of compounds of the formula (1) for the production of a pharmaceutical composition having integrin-antagonistic action and in particular for the therapy and prophylaxis of cancer, osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis and ophthalmic disorders.

H17-02-00

THIS PAGE BLANK (USPTO)